Aller au contenu
Trouver un autre spécialiste

Brigitte Guérin

Professeure, Faculté de médecine et des sciences de la santé
FMSS Dép. sciences imagerie médicale et radiations

Présentation

Sujet de recherche

Chemical Synthesis and Catalysis, Organic Molecules and Biomolecules, Cancer Diagnosis and Detection, Breast Cancer, Prostate Cancer

Disciplines de recherche

Nuclear Medicine, Chemistry

Mots-clés

Bifunctional Chelator, In vitro and in vivo animal studies, PET tracer development, Preclinical imaging, Radiochemistry, Radiolabelling, Radiometal for targeted radiotherapy, Radiometal production by Cyclotron, Theranostic development, Translational studies

Intérêts de recherche

Trained in organic chemistry, medicinal chemistry and radiochemistry, my research focuses on the development of radiometal produced by cyclotron, bifuctional chelators for radiometal labeling and theranostics for early detection and treatment of cancer recurrence. These are important tools that help characterize and accurately pinpoint the exact stage of development of the disease. This research paves the way to personalized medicine and on-target cancer treatments.

Centre de recherche

Centre de recherche du CHUS

Langues parlées et écrites

Anglais, Français

Diplômes

(2007). (Post-doctorate, Postdoctorate in Chemistry). Université de Sherbrooke.

(1995). (Post-doctorate, Postdoctorate in Chemistry). Université de Montréal.

(1994). (Doctorate, Doctorate in Chemistry). Université de Sherbrooke.

(1988). (Bachelor's, Bachelor in Chemistry). Université de Sherbrooke.

Prix et distinctions

  • (2025) Research Chair Jeanne et Jean-Louis Lévesque de radiobiologie. Université de Sherbrooke. (Prize / Award).
  • (2019) 2018 Clara Benson Award Winner. Sponsored by the Canadian Council of University Chemistry Chairs (CCUCC),. Chemical Institute of Canada/Canadian Society for Chemistry. (Prize / Award).
  • First Winner- Category Quality of Care and Services: 68Ga-DOTA-TATE--. Centre intégré universitaire de santé et des services sociaux de l'Estrie (CIUSSE)-CHUS. (Distinction).
  • Innovation Prize,. Université de Sherbrooke. (Prize / Award).
  • Mérite Estrien for my leadership in the cyclotron-produced Tc-99m project. La Tribune for a regional recognition. (Distinction).
  • Prix Hippocrate pour l’innovation interdisciplinaire en matière de qualité et de sa gestion / Hippocrate Prize for interdisciplinary innovation in quality and its management. MSSS. (Prize / Award).
  • Prix d'excellence de groupe, catégorie Rayonnement for a national effort to develop an alternative production method for Tc-99m using cyclotron. Centre Hospitalier Univ. de Sherbrooke. (Distinction).
  • Prix du Doyen au Gala du Mérite Dean's Award Production of Tc-99m by cyclotron. Université de Sherbrooke. (Distinction).
  • Prix d’excellence 2023-2024 du CIUSSS de l’Estrie – CHUS dans la catégorie Mission universitaire et rayonnement. / Excellence. CIUSSS de l’Estrie – CHUS. (Prize / Award).
  • Prix Éric-Marsault. Université de Sherbrooke. (Prize / Award).
  • chercheuse de l’année au CRCHUS/Researcher of the year at the CRCHUS. CRCHUS/CIUSSSE. (Prize / Award).

Financement

  • Grant. (Awarded). Co-applicant. Rare Isotopes to Transform Cancer Therapy. New Frontiers in Research Fund (Tri-Agency Institutional funding). New Frontiers in Research Fund-Transformation. 23 796 774 $. (2023-2029)
  • Grant. (Awarded). Co-applicant. Imaging the contribution of early cerebrovascular inflammation in Alzheimer's disease. Canadian Institutes of Health Research (CIHR). Project grant. 1 002 150 $. (2022-2027)
  • Grant. (Awarded). Co-investigator. Étude des interactions supramoléculaires de feuillets bêta de l’amyloïde modulée par les azapeptides pour mieux comprendre la base structurelle des maladies amyloïdes et faciliter leur détection précoce. Fonds Québécois de la Recherche sur la Nature et les Technologies (FQRNT). PROJET DE RECHERCHE EN ÉQUIPE. 63 500 $. (2023-2027)
  • Research Chair. (Awarded). Principal Applicant. Chaire Jeanne et Jean-Louis Lévesque de radiobiologie. Fonds Institutionnel de Recherche de l'Université de Sherbrooke. Chaire institutionnelle. 575 000 $. (2021-2025)
  • Grant. (Awarded). Co-investigator. Le Consortium Acuité-Qc : prédire et visualiser l’action du médicament. Ministère de l’Économie et de l’Innovation. 2e appel à propositions du Fonds d’Accélération des collaborations en santé (FACS). 13 850 000 $. (2021-2024)
  • Grant. (Awarded). Principal Applicant. Établir un corridor de service en imagerie par tomographie d’émission de positrons au 68Ga-DOTA-TATE afin d’assurer le maintien d’un service diagnostique clé pour les cancers exprimant les récepteurs de la somatostatine.. MEDTEQ. Fonds de soutien à l’innovation en santé et services sociaux (FSISSS)-volet 2. 240 000 $. (2022-2024)
  • Grant. (Awarded). Co-applicant. High affinity inhibitors of PACE4 with therapeutic implications for prostate cancer. Canadian Institutes of Health Research (CIHR). Project grant. 696 150 $. (2019-2024)
  • Grant. (Awarded). Principal Applicant. Tools for the preparation of peptide-based radioligands. Natural Sciences and Engineering Research Council of Canada (NSERC). Discovery grant. 145 000 $. (2019-2024)
  • Grant. (Completed). Co-investigator. Combined 4FMFES and FDG-PET imaging in advanced breast cancer: a phase II study. Canadian Breast Cancer Foundation (CBCF). Innovation to Impact Grants. 449 668 $. (2020-2023)
  • Grant. (Completed). Principal Investigator. Optimizing care for castration-resistant prostate cancer patients using triple-tracer molecular imaging and targeted radioligand therapy. Oncopole. Oncopole-EMC2. 1 500 000 $. (2018-2023)
  • Grant. (Completed). Co-investigator. Etude des interactions supramoléculaires des feuillets pour la détection précoce et la désagrégation des protéines amyloïdes. Fonds Québécois de la Recherche sur la Nature et les Technologies (FQRNT). Team grant. 190 500 $. (2020-2023)
  • Grant. (Completed). Principal Applicant. Implantation des normes BPL et BPF pour la plateforme d’imagerie du CIMS-CRCHUS. Ministère de l’Économie et de l’Innovation. Soutien aux plateformes technologiques stratégiques du MÉI. 585 666 $. (2019-2023)
  • Grant. (Completed). Principal Investigator. Concours IPS-Innovation 2020. Institut de Pharmacologie de Sherbrooke. Concours IPS-Innovation 2020. 30 000 $. (2021-2023)
  • Grant. (Completed). Co-applicant. Imaging, understanding, and managing radiotherapy inflammation and radiation necrosis. Canadian Institutes of Health Research (CIHR). Project grant. 914 175 $. (2017-2022)
  • Grant. (Completed). Principal Applicant. Développement d'un agent d'imagerie par tomographie par émission de positrons (TEP) pour la détection de la sclérose latérale amyotrophique (SLA). Ministère de l’Économie et de l’Innovation. Projets de maturation technologique. 354 043 $. (2021-2022)
  • Grant. (Completed). Co-investigator. Early detection and in vivo estrogen receptor status determination of uterine and ovarian cancers using the novel PET tracer 4FMFES: a phase I/II study. Canadian Cancer Society. Innovative Grants - 2018. 199 672 $. (2018-2021)
  • Grant. (Completed). Principal Investigator. APPROVISIONNEMENT EN TECHNÉTIUM AU QUÉBEC. Ministère de la Santé et des Services Sociaux (MSSS). N/A. 859 905 $. (2017-2020)
  • Research Chair. (Completed). Principal Applicant. Chaire Jeanne et Jean-Louis Lévesque de radiobiologie. Fonds Institutionnel de Recherche de l'Université de Sherbrooke. Chaire institutionnelle. 575 000 $. (2016-2020)
  • Grant. (Completed). Principal Applicant. Conception et réalisation d'une unité de synthèse automatisée pour la préparation du [18F]-FMPEP-d2.. Natural Sciences and Engineering Research Council of Canada (NSERC). EGP - Subventions d'engagement partenarial pour les universités. 25 000 $. (2019-2020)
  • Grant. (Completed). Co-investigator. Imaging agents for the early detection of amyloid and neurodegenerative diseases. Fonds de recherche du Québec - Santé (FRQS). Partenariat MOST/ FRQNT/FRSQ. 150 000 $. (2017-2020)
  • Grant. (Completed). Principal Applicant. Optimiser les soins des patients atteints du cancer de la prostate résistant à la castration. Fondation du CHUS/Bombardier produits récréatifs. N/A. 300 000 $. (2019-2020)
  • Grant. (Completed). Co-applicant. Biopsie corps entier du cancer du sein par imagerie TEP: Meilleur diagnostic non-invasif pour un traitement plus personnalisé. Fonds Jean-Luc Mongrain et de la Fondation du CHUS. N/A. 50 000 $. (2018-2019)
  • Grant. (Completed). Principal Investigator. Développement d’un nouveau traceur TEP de l’activité microgliale et validation en contexte de douleur chronique. RQRD-RBIQ. Concours de subvention inter-réseaux RQRD-RBIQ 2017-2018. 20 000 $. (2018-2019)
  • Grant. (Completed). Co-investigator. Vers l’exploitation de biopsies pancorporelles non-invasives dans le cancer du sein : développement d’une capacité multicentrique en vue d’une étude de phase II d’imagerie TEP ciblant les récepteurs d’estrogène (ER) et HER2 à l’aide du 4FMFES et du 8. RBIQ. INITIATIVE STRATÉGIQUE. 25 000 $. (2018-2019)
  • Grant. (Completed). Co-applicant. Imagerie TEP des récepteurs d’œstrogène au 4FMFES : du cancer du sein vers les cancers gynécologiques. Centre de Recherche du Centre Hospitalier de l'Université de Sherbrooke (CRCHUS). PAFI. 25 000 $. (2018-2019)
  • Grant. (Completed). Principal Applicant. Fight hypoxia for personalized brain cancer therapy. Merck Sharp & Dohme. Don de Merck Sharp & Dohme. 50 000 $. (2016-2017)

Publications

Articles de revue

  • JA. Rousseau; M. Maier, S. Ait-Mohand; V. Dumulon-Perreault, O. Sarrhini; S. Tremblay, E. Rousseau, M. Salzmann, B. Guérin. (2024). Antibody-based PET imaging of misfolded SOD1 in an amyotrophiclateral sclerosis mouse model. J. Nucl. Med. N/A (N/A), N/A. (Revision Requested).
  • R. Nehmé, M. Fortier, M. Létourneau, B. Guérin, V. Dumulon-Perreault, S. Ait Mohand, O. Sarrhini, S. T. Larda, Y. Castellanos Villamizar, M. Bernier, N. Porębska L. Opalinski, C. Fuselier, P. Granger Joly de Boissel, A. Dumoulin, D. Chatenet, N. Doucet, Y. St-Pierre. (2024). Development of Galectin-7-Specific Nanobodies:Implications for Immunotherapy and Molecular Imaging in Cancer. Journal for ImmunoTherapy of Cancer N/A (N/A), N/A. (Submitted).
  • Huwaidi, A.; Robert, G.; Kumari, B.; Cloutier, P.; Bass, A.; Guérin, B.; Sanche, L.; Wagner, J.R. (2024). Electron-induced damage by UV photolysis of DNAattached to gold nanoparticles. Chem. Res. Toxicol. N/A N/A. (In Press).
  • Huwaidi, A.; Abdo, R-A.; Lessard, F.; Guérin, B.; Sanche, L.; Wagner, R. (2024). Gold nanoparticles size dependence on DNA damage underX-rays a LC:MS/MS study. ACS Applied Nano Materials N/A (N/A), N/A. (Submitted).
  • É. Montastier; R. Zhou Ye; C. Noll; M. Amrani; F. Frisch; M. Fortin; L. Bouffard; S. Phoenix; O. Sarrhini; S. C. Cunnane; B. Guérin; E. E. Turcotte; A. C. Carpentier. (2024). Nicotinic acid increases adipose tissue dietaryfatty acid trapping and reduces postprandial hepatic and cardiac fatty aciduptake in prediabetes. Cell Metabolism N/A (N/A), N/A. (Submitted).
  • F. Pouliot, MD*; F. Saad, MD; E. Rousseau, MD; P. O. Richard, MD; A. Zamanian, MSc; S. Probst, MD; E. Lévesque, MD; V. Castonguay, MD; N. Marcoux, MD; M. Lodde, MD; D. Juneau, MD; Z. Hamilou, MD; J.-B. Lattouf, MD; F.-A. Buteau, MD; M. Pavic, MD; J.-F. Castilloux, MD; B. Neveu, PhD; G. F. Bouvet, PhD; C. Allard, MSc; A. Tétu, MSc; B. Guérin, PhD*; J.-M. Beauregard, MD*. (2024). Prevalence ofintra-patient inter-metastatic heterogeneity in mCRPC patients based ontriple-tracer PET imaging: the 3TMPO cohort study. Journal of Nuclear Medicine September 2024, jnumed.124.268020; DOI: https://doi.org/10.2967/jnumed.124.268020 N/A (N/A), N/A. (Published).
  • Dumont, L.; Caron, A.; Richard, G.; Croteau, E.; Fortin, M.; Frisch, F.; Phoenix, S.; Dubreuil, S.; Guérin, B.; Turcotte, E.E; Carpentier, A.C.; Blondin, D.P. (2024). The effects of the β1-adrenergic receptor antagonist bisoprololadministration on mirabegron-stimulated human brown adipose tissuethermogenesis. Acta Physiol. 240 (5), e14127. (Accepted).
  • Habashi, M.; Chauhan, P.; Vutla, S.; Senapati, S.; Diachkov, M. ; El-Husseini, A.; Guérin, B.**; Lubell, W.**; Rahimipour, S. **. (2023). J. Med. Chem. 66 3058–3072. (Published).
  • S. Tremblay*, J.-F. Beaudoin, O. Bélissant Benesty*, S. Ait-Mohand*, V. Dumulon-Perreault*, É. Rousseau, É. E. Turcotte, B. Guérin**. Selected as the “Featured Translational Science Article”. (2023). Clinical Trial withCyclotron-Produced [68Ga]Ga-DOTA-TATE: An Integrated Solution fromCyclotron Vault to Safety Assessment and Diagnostic Efficacy in NeuroendocrineCancer Patients. J. Nucl. Med. 64 211-218. (Published).
  • L. Ouyang, H. Lin, P. Zhuang, Y. Shao, M. Khosravifarsani*, B. Guérin, Y. Zheng and L. Sanche. (2023). DNA radiosensitization by terpyridine-platinum: damages induced by the 5and 10 eV transient anions. Nanoscale 15 (7), 3230-3242. (Published).
  • M.-C. Milot*, O. Bélissant Benesty*, V. Dumulon-Perreault*, S. Ait-Mohand*, S. Geha, P. O. Richard, E. Rousseau, B. Guérin**. (2023). Theranostic 64Cu-DOTHA2-PSMA allows low toxicity radioligand therapy in mice prostate cancer model. Front Oncol. 13 1073491. (Published).
  • M. Paquette,E. Espinosa-Bentancourt,E. Lavallee, *S. Phoenix,K. Lapointe-Milot, P. Bessette, B. Guerin, E. E Turcotte. (2022). 18F-4FMFES and 18F-FDG PET/CT in ER+endometrial carcinomas: preliminary report. Journal of Nuclear Medicine 63 702-707. (Published).
  • *M.-C. Milot, *O. Bélissant Benesty, *V. Dumulon-Perreaulty, *S. Ait-Mohand, P. O. Richard, E. Rousseau, B. Guérin. (2022). 64Cu-DOTHA2-PSMA, aPSMA PET radiotracer for prostate cancer with a longimaging time window. Pharmaceuticals 15 996. (Published).
  • *S. Tremblay, J.-F. Beaudoin, *O. Bélissant Benesty, *S. Ait-Mohand, *V. Dumulon-Perreault, É. Rousseau, É E Turcotte, B. Guérin. (2022). 68Ga-DOTATATE Preparedfrom Cyclotron Produced Gallium-68:An Integrated Solution from Cyclotron Vaultto Safety Assessment and Diagnostic Efficacy in Neuroendocrine Cancer Patients. J. Nucl Med N/A N/A. (Accepted).
  • M. Habashi, S. Vutla, K. Tripathi, S. Senapati, P. S. Chauhan, A, Haviv-Chesne, M. Richman, Ait Mohand, S.*; Dumulon-Perreault, V.*; R. Mulamreddy, E. Okun, J. H. Chill, B. Guérin**, W. D. Lubell**, S. Rahimipour** *students and PHQ; ** Co-last authors. (2022). Early detection and treatment of Alzheimer’s disease by targeting toxic soluble Ab oligomers. PNAS 119 (49), e2210766119. (Published).
  • T. Tippayamontri, E. Betancourt-Santander, B. Guérin, R. Lecomte, B. Paquette, L. Sanche. (2022). Estimation of the internal dose imparted by 18F-Fluorodeoxyglucose to tissues by using Frickedosimetry in a phantom and positron emission tomography. Front. Nucl. Med. 815141 N/A. (Published).
  • G. Richard, D. P. Blondin, S. A. Syed, M. Shah, M. Fortin, S. Phoenix, F. Frisch, S. Dubreuil, B. Guérin, É. E. Turcotte, M. Lepage, J. D. Schertzer, G. R. Steinberg, K. M. Morrison, A. C. Carpentier. (2022). High-fructose feeding suppresses cold-stimulatedbrown adipose tissue glucose uptake independently of changes inthermogenesis and the gut microbiome. Cell Rep Med. 3 (9), 100742. (Published).
  • *M. Khosravifarsani, *S. Ait-Mohand, B.Paquette, L. Sanche, B, Guérin. (2022). In vivo behavior of [ 64Cu]NOTA-terpyridine platinum, a novel chemoradio-theranostic agent for imagingand therapy of colorectal cancer. Frontiers in Medicine 9 975213. (Published).
  • R. Z. Ye, É. Montastier, C. Noll, F. Frisch, M. Fortin, L. Bouffard, *S. Phoenix, B. Guérin, É. E. Turcotte, A. C. Carpentier. (2022). Total postprandialhepatic non-esterified and dietary fatty acid uptake is 2 increased andinsufficiently curbed by adipose tissue fatty acid trapping in prediabetes. Diabetes 71 (9), 1891-1901. (Published).
  • *Déry L., Charest G., Guérin B., Akbari M, Fortin D. (2021). Chemoattraction ofneoplastic glial cells with CXCL10, CCL2 and CCL11 as a paradigm for apromising therapeutic approach for primary brain tumors. Int. J. Mol. Sci. 22 12150. (Published).
  • *M. Khosravifarsani, *S. Ait-mohand, B. Paquette, L. Sanche, B. Guérin. (2021). Design, Synthesis, and Cytotoxicity Assessment of [64Cu]Cu-NOTA-Terpyridine Platinum Conjugate:A Novel Chemoradiotherapeutic Agent with Flexible Linker. Nanomaterials 11 2154. (Published).
  • *M. Khosravifarsani, *S. Ait-mohand, B. Paquette, L. Sanche, B. Guérin. (2021). High Cytotoxic Effect by Combining Copper-64 withNOTA-Terpyridine Platinum Conjugates. J. Med. Chem. 64 (10), 6765-6776. (Published).
  • É. Montastier, R. Z. Ye, C. Noll, L. Bouffard, M. Fortin, F. Frisch, *S. Phoenix, B. Guérin, É. E Turcotte, G. F. Lewis, A. C. Carpentier. (2021). Increased postprandial nonesterified fatty acid flux in prediabetes is tempered byenhanced dietary fatty acid trapping in adipose tissues. Am J Physiol Endocrinol Metab. 320 E1093–E1106. (Published).
  • *H. Ali; B. Guérin; J.E. van Lier. (2021). Pd-catalyzed Cross-Coupling Reactions of gemDibromovinyl Boron Dipyrrins. Eur. J Org Chem 2021 (22), 3123-2132. (Published).
  • *H. Ali; B. Guérin; J.E. van Lier. (2021). Pd-catalyzed synthesisof C-C (Sonogashira, Suzuki, Heck, Stille), C-P and C-S linkedproducts using gem-dibromovinyl BODIPY. Acceptedin. J. Porphyrins Phthalocyanines N/A N/A. (Accepted).
  • *Huwaidi, A.; Kumari, B.; Robert, G.; Guérin, B.; Sanche, L.; Wagner. (2021). Profiling DNA DamageInduced by the Irradiation of DNA with Gold Nanoparticles. J Phys Chem Lett. 12 (40), 9947–9954. (Published).
  • *M. Khosravifarsani, *S. Ait-mohand, B. Paquette, L. Sanche, B. Guérin. (2021). Synthesis, and Cytotoxicity Assessment of [64Cu]Cu-NOTA-Terpyridine Platinum Conjugate:A Novel Chemoradiotherapeutic Agent with Flexible Linker. Nanomaterials 11 2154. (Published).
  • F. Pouliot, J.-M. Beauregard, D. Trudel, F. Saad, P. O. Richard, É. Turcotte, É. Rousseau, S. Probst, W. Kassouf, M. Anidjar, F. Camirand Lemyre, G. F. Bouvet, B. Neveu, A Tétu, B Guérin. (2021). TheTriple-Tracer strategy against Metastatic PrOstate cancer (3TMPO) studyprotocol. BJU Int. N/A N/A. (Published).
  • *S. Kahn Ali, *S. Ait-Mohand, *V. Dumulon-Perreault, B. Guérin. (2021). [68Ga]Ga-4HMSA a promising new PET tracer for imaging inflammation. EJNMMI Res. 11 (1), 114. (Published).
  • M. Paquette, *S. Phoenix, C. Lawson, B. Guérin, R. Lecomte, L.-H. Tai, É. E. Turcotte, J. V. Leyton. (2020). A preclinical PETdual-tracer imaging protocol for ER and HER2 phenotyping in breast cancer xenografts. EJNMMI Research 10 (69), 1-13. (Published).
  • *A. H. Alnahwi, *S. Tremblay, *S. Ait-Mohand, *V. Dumulon-Perreault, J.-F. Beaudoin and B. Guérin. (2020). Automated radiosynthesisof 68Ga for large-scale routine production using 68Zn pressed target. Applied Radiation and Isotopes 156 109014. (Published).
  • A.-M. Carreau, C. Noll, D. P. Blondin, F. Frisch, M. Nadeau, M. Pelletier, *S. Phoenix, S. C. Cunnane, B. Guérin, E. E. Turcotte, L. Biertho2 A. Tchernof, and A. C. Carpentier. (2020). Bariatric surgery rapidly decreases cardiacdietary fatty acid partitioning and hepatic insulin resistance throughincreased intra-abdominal adipose tissue storage and reduced spillover in type2 diabetes. Diabetes 69 (4), 567-577. (Published).
  • G. Richard, C. Noll, M. Archambault, R. Lebel, L. Tremblay, *S. Ait-Mohand, B. Guérin, D. P. Blondin, A. C. Carpentier, M. Lepage. (2020). Contribution of perfusion to the 11C-acetate signal in brown adipose tissue assessedby DCE-MRI and 68Ga-DOTA PET in a rat model. Magnetic Resonance in Medicine. DOI: 10.1002/mrm.28535 85 (3), 1625-1642. (Published).
  • M. Paquette; *S. Phoenix; É. Lavallée; J.A. Rousseau; B. Guérin; É.E. Turcotte; R. Lecomte. (2020). Cross-species physiological assessment of brainestrogen receptor expression using 18F-FES and 18F-4FMFESPET imaging. Molecular Imaging and Biology 22 1403-1413. (Published).
  • D. P. Blondin, S Nielsen, E. N. Kuipers, M. C. Severinsen, V. H. Jensen, S. Miard, N. Z. Jespersen, S. Kooijman, M. R. Boon, M. Fortin, *S. Phoenix, F. Frisch, B. Guérin, É. E. Turcotte, F. Haman, D. Richard, F. Picard, P. C.N. Rensen, C. Scheele, A. C. Carpentier. (2020). Human brown adipocyte thermogenesis is driven by the β2-AR stimulation. Cell Metabolism 32 (2), 287-300. (Published).
  • A.R. Jalilian, J.A. Osso Jr., J. Vera-Araujo, V. Kumar, M.J. Harris, B. Gutfilen, B. Guérin, H. Li, F. Zhuravlev, R. Chakravarty, B. Alirezapour, M. A. Ávila-Rodríguez, I. Ullah Khan, I. Aljammaz, T. Assaad , G. Luurtsema, J. Smith, A. Duatti. (2020). IAEA contribution to the development of copper-64 radiopharmaceuticals for theranostic applications. The Quarterly Journal of Nuclear Medicine and Molecular Imaging 64 (4), 338-345. (Published).
  • *A. H. Alnahwi, *S. Ait-Mohand, *V. Dumulon-Perreault, Y. L. Dory, and B. Guérin. (2020). Promising performance of4HMS, a New Zirconium-89 Octadentate Chelator. ACS Omega 5 (119), 10731–10739. (Published).
  • C. Noll; É. Montastier; M. Amrani; M. Kunach; F. Frisch; M. Fortin; L. Bouffard; S. Dubreuil; *S. Phoenix; S. C. Cunnane; B. Guérin; E. E. Turcotte; M, Laville and A. C. Carpentier. (2020). Seven-day overfeeding enhances adipose tissuedietary fatty acid storage and decreases myocardial and muscle dietary fattyacid partitioning in healthy subjects. Am J Physiol Endocrinol Metab 318 (2), E286-E296. (Published).
  • *H. Ali; B. Guérin; J.E. van Lier. (2020). gemSynthesis, spectral andcrystal structures of -dibromovinyl boron dipyrrins. Dyes and Pigments 179 108399. (Published).
  • A. Kwiatkowska, F. Couture, *S. Ait-Mohand, R. Desjardins, Y. L. Dory, B. Guérin, and R. Day. (2019). Enhanced anti-tumor activity of the Multi-Leu peptide PACE4 inhibitor transformed intoan albumin-bound tumor-targeting prodrug. Scientific Reports 9 2018. (Published).
  • F. Alves, S. Bertrand, T. Degrado, K. Gagnon, B. Guérin, C. Hoehr, M. Pandey, *S. Tremblay. (2019). Gallium-68Cyclotron Production. IAEA TECDOC-1863 N/A N/A. (Published).
  • T, Tippayamontri, B. Guérin, *R. Ouellet, O. Sarrhini, J. Rousseau, R. Lecomte, B. Paquette and L. Sanche. (2019). Intra-tumoral18F-FLT infusion in metabolic targeted radiotherapy. EJNMMI Research 9 33. (Published).
  • *J.-L., Beaudeau; V. Blais, B. Holleran, G. Pineyro, B. Guérin, L. Gendron, Y. Dory. (2019). N-guanidyland C-tetrazole Leu-Enkephalin Derivatives: Efficient Delta Opioid ReceptorAgonists with Improved Pharmacological Properties. ACS Chemical Neuroscience 10 (3), 1615-1626. (Published).
  • *H. Ali; J.E. van Lier; B. Guérin. (2019). Radiolabeled BODIPYs: AnOverview. J. Porphyrins Phthalocyanines 23 781–796. (Published).
  • *H. Ali; B. Guérin; J.E. van Lier. (2019). gem-DiBromovinylBoron Dipyrrins: Synthesis, Spectral Properties and Crystal Structures. Dalton Trans. 48 (30), 11492-11507. (Published).
  • *A. H. Alnahwi, *S. Tremblay, B. Guérin. (2018). ComparativeStudy with 89Y-foil and 89Y-pressed Targets for theProduction of 89Zr. Appl. Sci. 8 1579. (Published).
  • *N. Mansour, *M. Paquette, S. Ait-Mohand*, V. Dumulon-Perreault*, B. Guérin. (2018). Evaluation of a novel GRPR antagonist for prostate cancer PET imaging: [64Cu]-DOTHA2-PEG-RM26. Nuclear Medicine and Biology 56 31–38. (Published).
  • D. Bella Ndong,V Blais, B. J. Holleran, A. Proteau-Gagne, I. Cantin-Savoie, W Robert, J.-F. Nadon, S. Beauchemin, R. Leduc, G Pineyro, B. Guerin, L. Gendron, Y. L. Dory. (2018). Explorationof the fifth position of leu-enkephalin and its role in binding and activatingdelta (DOP) and mu (MOP) opioid receptors. Peptide Science 111 (1), e24070. (Published).
  • *M. Paquette, É. Lavallée, *S. Phoenix, *R. Ouellet, H. Senta, J. E. van Lier, B. Guérin, R. Lecomte, and É. E. Turcotte. (2018). Improved Estrogen Receptor assessment by PET using the novel tracer 4FMFES over FES inER+ breast cancer patients in an ongoing phase II clinical trial. J. Nucl. Med. 59 197-203. (Published).
  • *S. Beaudoin, *M. Paquette, L. Fafard-Couture, M.A. Tremblay, R. Lecomte, B. Guerin, and J.V. Leyton. (2018). Initial evaluation of antibody-conjugates modified with viral-derived peptides for increasingcellular accumulation and improving tumor targeting. Journal of Visualized Experimentation (JOVE) 133 N/A. (Published).
  • *M. Paquette, *S. Beaudoin, M.-A.Tremblay, S. Jean, A. Lopez, R. Lecomte, B. Guérin, M. Bentourkia, R. Sabbagh, J Leyton. (2018). NLS-cholic acid conjugation to IL-5R?-specific antibody improves cellular accumulation andin vivo tumor-targeting properties in a bladder cancer model. Bioconjug. Chem. 29 (4), 1352–1363. (Published).
  • René Ouellet*, Sébastien Tremblay*, Brigitte Guérin. (2017). A new simple method for the purification of sodium pertechnetate produced by cyclotron and therecycling of molybdenum. Nuclear Medicine and Biology (Submitted).
  • *S. Osati, *H. Ali, F. Marques, M. Paquette*, S. Beaudoin*, B. Guerin, J. V. Leyton, J. E. van Lier. (2017). BODIPY-17a-ethynylestradiol conjugates: Synthesis,fluorescence properties and receptor binding affinities. Bioorganic & Medicinal Chemistry Letters 27 443–446. (Published).
  • D.P. Blondin, H. C. Tingelstad, C.Noll, F. Frisch, S. Phoenix*, B. Guérin, É. E. Turcotte, D. Richard, F Haman, A. C. Carpentier. (2017). Dietary fatty acid metabolism of brown adipose tissue in cold-acclimatedmen. Nature Communications 14146 N/A. (Published).
  • N. Mansour,* V. Dumulon-Perreault*, S. Ait-Mohand*, M. Paquette,* R. Lecomte, B. Guérin. (2017). Impact of charged linker on biodistribution of [64Cu]NOTA peptide-based GRPR antagonists. Labelled Compounds and Radiopharmaceuticals 60 (4), 200-212. (Published).
  • D.P. Blondin, F. Frisch, S. Phoenix*, B. Guérin, É. E. Turcotte, D. Richard, F. Haman, A. C. Carpentier. (2017). Inhibition of intracellular triglyceride lipolysis suppresses coldinduced brown adipose tissue metabolism and increases shivering in humans. Cell Metab. 25 438-447. (Published).
  • F. Panet, F. Couture*, A. Kwiatkowska, R. Desjardins, B. Guérin , R. Day. (2017). PACE4 is an important driver of ZR-75-1 estrogen receptor-positive breast cancer proliferation andtumor progression. European Journal of Cell Biology 96 (5), 469-475. (Published).
  • *S.V. Selivanova, É. Lavallée, H. Senta, L. Caouette, A. J. McEwan, B. Guérin, R. Lecomte, É. Turcotte. (2017). Phase I clinical trial using sodium pertechnetate 99mTc produced with a medium-energycyclotron. Journal of Nuclear Medicine 58 (5), 791-798. (Published).
  • *S. Osati, *H. Ali, B. Guérin and J. E. van Lier. (2017). Steroid-photosensitizerconjugates: Syntheses and applications. Journal of Porphyrins and Phthalocyanines 21 701–730. (Published).
  • A Pirisedigh,* V. D. Blais, S. Ait-Mohand*, K. Abdallah, B. J. Holleran, R. Leduc, Y. L. Dory, L. Gendron, B. Gue?rin. (2017). Synthesis and Evaluation of a Novel 64Cu/NOTA-TIPP Conjugate, a Selective?-Opioid Receptor PET Imaging Agent. Organic Letters 19 (8), 2018-2021. (Published).
  • S. Osati*; H. Ali*; B. Guérin; J. E. van Lier. (2017). Synthesis and spectral properties of estrogen- and androgen-BODIPY conjugates. Steroids 123 27–36. (Published).
  • *M. Paquette, L.-G. Perez-Vilera, *S. Beaudoin, N. Ekindi-Ndongo, P.-L. Boudreaut, M.-A. Bonin, M.-C. Battista, M. Bentourkia, A. Lopez, R. Lecomte, E. Marsault, B. Guerin, R. Sabbagh, and J. Leyton. (2017). Targeting IL-5R? with antibody-conjugates reveals a strategy for imaging and therapy for invasive bladder cancer. OncoImmunology 6 (10), e1331195. (Published).
  • *J.-F.Nadon, K. Rochon, G. Langlois, S. Grastilleur, B. Guérin, L. Gendron, Y. Dory. (2017). ZSynthesis of Gly-?[()CF=CH]-Phe,a fluoroalkene dipeptide isostere and its incorporation into a Leu-enkephalinpeptidomimetic. ACS Chemical Neuroscience 8 (1), 40-49. (Published).
  • M. Shi,* B. Paquette, T. Thippayamontri, L. Gendron, B. Guérin & L. Sanche. (2016). Increased radio-sensitivity of colorectal tumor with intra-tumoral injection of low doseof gold nanoparticles. International Journal of Nanomedicine 11 5323-5333. (Published).
  • C. Zhang, J. Pan, K.-S. Lin, I. Dude, J. Lau, H. Merkens, S. Jenni, B. Guérin, F. Bénard. (2016). Targeting the neuropeptide Y1 receptor for cancer imaging by positron emission tomographyusing novel truncated peptides. Molecular Pharmaceutics N/A (7), 3657-3664. (Published).
  • D P. Blondin, S M. Labbé, S Phoenix*, B Guérin, É E. Turcotte, D Richard, A C. Carpentier, and F Haman. (2015). Contributions of white and brown adipose tissues and skeletal muscles to acute cold-induced metabolic response in healthy men. Journal of Physiology 593 (3), 701-14. (Published).
  • Couture F*, Ly K, Levesque C, Kwiatkowska A, Ait-Mohand S*, Desjardins R, Guérin B, Day R. (2015). Multi-Leu PACE4 Inhibitor Retention within Cells Is PACE4 Dependent and a Prerequisite for Antiproliferative Activity. Biomed Res Int. 2015 824014. (Published).
  • C. Levesque , F. Couture*, A .Kwiatkowska, R. Desjardins , B. Guérin , W. Neugebauer, R. Day. (2015). PACE4 Inhibitors and Their Peptidomimetic Analogs Block Prostate Cancer Tumor Progression Through Quiescence Induction, Increased Apoptosis and Impaired Neovascularisation. Oncotarget 6 (6), 3680-93. (Published).
  • Selivanova SV*, Lavallée É, Senta H, Caouette L, Sader JA, van Lier EJ, Zyuzin A, van Lier JE, Guérin B, Turcotte É, Lecomte R. (2015). Radioisotopic Purity of Sodium Pertechnetate 99mTc Produced with a Medium-Energy Cyclotron: Implications for Internal Radiation Dose, Image Quality, and Release Specifications. J Nucl Med. 56 (10), 1600-8. (Published).
  • D. P. Blondin, S. M. Labbé, C. Noll, M. Kunach, S. Phoenix*, B Guérin, É E. Turcotte, F Haman, D Richard, A C. Carpentier. (2015). Selective impairment of glucose, but not fatty acid or oxidative metabolism in brown adipose tissue of subjects with type 2 diabetes. Diabetes 64 (7), 2388-97. (Published).
  • Noll C, Kunach M, Frisch F, Bouffard L, Dubreuil S, Jean-Denis F, Phoenix S*, Cunnane SC, Guérin B, Turcotte EE, Carpentier AC. (2015). Seven-day caloric and saturated fat restriction increases myocardial dietary fatty acid partitioning in impaired glucose-tolerant subjects. Diabetes 64 (11), 3690-9. (Published).
  • S. Ait-Mohand*, C. Denis,* G. Tremblay,* M. Paquette* and B. Guérin. (2014). Development of Bifunctional Chelates Bearing Hydroxamate Arms for Highly Efficient 64Cu Radiolabeling. Organic Letters 16 4512-4515. (Published).
  • M Kunach, C Noll, S Phoenix*, B Guérin, J-P Baillargeon, E E. Turcotte, AC. Carpentier. (2014). Effect of Sex and Impaired Glucose Tolerance on Organ-Specific Dietary Fatty Acid Metabolism in Humans. Diabetes 64 (7), 2432-41. (Published).
  • Labbé SM , Noll C , Grenier-Larouche T , Kunach M , Bouffard L , Phoenix S*, Guérin B , Baillargeon JP , Langlois MF , Turcotte EE , Carpentier AC. (2014). Improved cardiac function and dietary fatty acid metabolism after modest weight loss in subjects with impaired glucose tolerance. American journal of physiology. Endocrinology and metabolism 306 (12), E1388-E1396. (Published).
  • Blondin DP , Labbé SM , Christian Tingelstad H , Noll C , Kunach M , Phoenix S*, Guérin B , Turcotte EE , Carpentier AC , Richard D , Haman F. (2014). Increased brown adipose tissue oxidative capacity in cold-acclimated humans. The Journal of clinical endocrinology and metabolism 99 (3), E438–E446. (Published).
  • F Couture*, C Levesque, V Dumulon-Perreault, S Ait-Mohand, F D’Anjou, R Day*, B Guérin*. (2014). PACE4-based molecular targeting of prostate cancer using an engineered 64Cu-radiolabeled peptide inhibitor. Neoplasia 16 (8), 634-643. (Published).
  • Ranyuk E,* Lebel R , Bérubé-Lauzière Y , Klarskov K , Lecomte R , van Lier JE , Guérin B. (2013). (68)Ga/DOTA- and (64)Cu/NOTA-Phthalocyanine Conjugates as Fluorescent/PET Bimodal Imaging Probes. Bioconjugate chemistry 24 (9), 1624–1633. (Published).
  • Inkster J*, Lin KS , Ait-Mohand S*, Gosselin S*, Bénard F , Guérin B, Pourghiasian M , Ruth T, Schaffer P, Storr T. (2013). 2-Fluoropyridine prosthetic compounds for the (18)F labeling of bombesin analogues. Bioorganic & medicinal chemistry letters 23 (13), 3920-6. (Published).
  • Beaudoin J, Ekici S, Daldal F, Ait-Mohand S*, Guérin B, Labbé S. (2013). Copper transport and regulation in Schizosaccharomyces pombe. Biochem Soc Trans 41 (6), 1679–1686. (Published).
  • M. Kunach, C. Noll, S.M. Labbé, T. Grenier-Larouche, L. Bouffard, S. Phoenix, B. Guérin, J.P. Baillargeon, M.F. Langlois, E.E. Turcotte, A.C. Carpentier. (2013). Improved Cardiopulmonary Functional Capacity Following a One-Year Lifestyle Intervention Regimen Does Not Explain Improved Postprandial Myocardial Dietary Fatty Acid Metabolism in Patients with Impaired Glucose Tolerance. Can. J. Diabetes 37 (S4), S50. (Published).
  • Ranyuk E,* Cauchon N , Klarskov K , Guérin B , van Lier JE. (2013). Phthalocyanine-Peptide Conjugates: Receptor-Targeting Bifunctional Agents for Imaging and Photodynamic Therapy. Journal of Medicinal Chemistry 56 (4), 1520–1534. (Published).
  • Rochon K , Proteau-Gagné A, Bourassa P , Nadon JF , Côté J , Bournival V , Gobeil F , Guérin B, Dory YL , Gendron L. (2013). Preparation and Evaluation at the Delta Opioid Receptor of a Series of Linear Leu-Enkephalin Analogues Obtained by Systematic Replacement of the Amides. ACS chemical neuroscience DOI: 10.1021/cn40005 1204-16. (Published).
  • C. Noll, M. Kunach, S. Phoenix*, B. Guérin, E.E. Turcotte, A.C. Carpentier. (2013). Seven-Day Caloric and Saturated Fat Restriction Increases Myocardial Dietary Fatty Acid Partitioning in Subjects with Impaired Glucose Tolerance. Can. J. Diabetes 37 (S4), S70. (Published).
  • Proteau-Gagné A , Rochon K , Roy M , Albert PJ , Guérin B, Gendron L , Dory YL. (2013). Systematic replacement of amides by 1,4-disubstituted[1,2,3]triazoles in Leu-enkephalin and the impact on the delta opioid receptor activity. Bioorganic & medicinal chemistry letters 23 (19), 5267-9. (Published).
  • Lebel, R., Zarifyussefian, N., Letendre-Jauniaux, M., Daigle, O., Ranyuk, E.*, Van Lier, J., Guérin, B., Lecomte, R., Massonneau, M., Ducharme, M.-E., and Bérubé Lauzière,. (2013). Ultra-high sensitivity detection of bimodal probes at ultra-low noise for combined fluorescence and positron emission tomography imaging. Proc. SPIE 8574, Multimodal Biomedical Imaging VIII, SPIE BiOS - Photonics 85740M 1-7. (Published).
  • S M. Labbé, É E. Turcotte, B Guérin,R Lecomte et A C. Carpentier. (2012). Avancées de l’imagerie par tomographie d’émission par positrons pour l’élucidationdes mécanismes menant aux complications cardiométaboliques de l’obésité. Médecine Sciences Amérique 1 (4), 135-150. (Published).
  • Ouellet V, Labbé SM, Blondin DP, Phoenix S*, Guérin B, Haman F, Turcotte EE, Richard D, Carpentier AC. (2012). Brown adipose tissue oxidative metabolism contributes to energy expenditure during acute cold exposure in humans. The Journal of clinical investigation 122 (2), 545-52. (Published).
  • P. Fournier,* V. Dumulon-Perreault*, S. Ait-Mohand*, R. Langlois, F. Bénard, R. Lecomte and B. Guérin. (2012). Comparative study of 64Cu/NOTA-[D-Tyr6,?Ala11,Thi13,Nle14]BBN(6-14) monomer and dimers for prostate cancer PET imaging. EJNMMI Res. 2 (8), 8. (Published).
  • Bessi VL , Labbé SM, Huynh DN, Ménard L, Jossart C, Febbraio M, Guérin B, Bentourkia M, Lecomte R, Carpentier AC, Ong H, Marleau S. (2012). EP 80317, a selective CD36 ligand, shows cardioprotective effects against post-ischaemic myocardial damage in mice. Cardiovascular research 96 (1), 99-108. (Published).
  • Labbé SM, Grenier-Larouche T, Noll C , Phoenix S*, Guérin B, Turcotte EE, Carpentier AC. (2012). Increased myocardial uptake of dietary fatty acids linked to cardiac dysfunction in glucose-intolerant humans. Diabetes 61 (11), 2701-10. (Published).
  • Fournier P,* Dumulon-Perreault V*, Ait-Mohand S*, Tremblay S*, Bénard F, Lecomte R, Guérin B. (2012). Novel radiolabeled peptides for breast and prostate tumor PET imaging: (64)Cu/and (68)Ga/NOTA-PEG-[D-Tyr(6),?Ala(11),Thi(13),Nle(14)]BBN(6-14). Bioconjugate chemistry 23 (8), 1687-93. (Published).
  • A. Radulska, S. Ait-Mohand*, V. Dumulon-Perreault*, R. Lebel, R. Zriba, B. Guérin, W.Neugebauer, M. Lepage. (2012). Stability studies on MMP-2 specific peptides for the preparation of molecular probes. Proceedings of the 32nd European Peptide Symposium, George Kokotos, Violetta Constantinou-Kokotou, John Matsoukas (Editors)European Peptide Society N/A 228-9. (Published).
  • Inkster JA, Liu K, Ait-Mohand S*, Schaffer P, Guérin B, Ruth TJ, Storr T. (2012). Sulfonyl fluoride-based prosthetic compounds as potential (18) f labelling agents. Chemistry, A Europeen Journal 18 (35), 11079-87. (Published).
  • Ait-Mohand S, Fournier P,* Dumulon-Perreault V, Kiefer GE, Jurek P, Ferreira CL, Bénard F, Guérin B. (2011). Evaluation of 64Cu-labeled bifunctional chelate-bombesin conjugates. Bioconjugate chemistry 22 (8), 1729-35. (Published).
  • A. Proteau-Gagné, J.-F. Nadon, S. Bernard, B. Guérin,* L. Gendron* and Y. L. Dory. (2011). Kinetic deconjugation: a gateway to the synthesis of Xxx-Gly (E)-alkene dipeptide isosteres. Tetrahedron Letters 52 (49), 6603-6605. (Published).
  • Labbé SM , Croteau E , Grenier-Larouche T , Frisch F , Ouellet R , Langlois R , Guérin B , Turcotte EE , Carpentier AC. (2011). Normal postprandial nonesterified fatty acid uptake in muscles despite increased circulating fatty acids in type 2 diabetes. Diabetes 60 (2), 408-15. (Published).
  • Labbé SM, Grenier-Larouche T, Croteau E, Normand-Lauzière F, Frisch F, Ouellet R, Guérin B, Turcotte EE, Carpentier AC. (2011). Organ-specific dietary fatty acid uptake in humans using positron emission tomography coupled to computed tomography. Am J Physiol Endocrinol Metab. 300 (3), E445-53. (Published).
  • Ranyuk ER,* Cauchon N, Ali H, Lecomte R, Guérin B, van Lier JE. (2011). PET imaging using 64Cu-labeled sulfophthalocyanines: synthesis and biodistribution. Bioorg Med Chem Lett. 21 (24), 7470-3. (Published).
  • Ali H, Ait-Mohand S, Gosselin S,* van Lier JE, Guérin B. (2011). Phthalocyanine-peptide conjugates via palladium-catalyzed cross-coupling reactions. The Journal of Organic Chemistry 76 (6), 1887-90. (Published).
  • S. M. Aly,* H. Guernon, B. Guérin, and P. D. Harvey. (2011). Polyoligopeptides Functionalized Zinc(II)porphyrins. A Step Towards Artificial Hemes. J. Porphyrins Phthalocyanines 15 1–12. (Published).
  • B. Guérin, A. Zyuzin, S. Tremblay, E. J. van Lier, S. Rodrigue, J. A. Rousseau, V. Dumulon-Perreault, R. Lecomte, and J. E. van Lier. (2010). Comparing Cyclotron- with generator- produced 99mTc. In Technetium and Other Radiometals in Chemistry and Medicine, Edited by Ulderico Mazzi, William C. Eckelman, Wynn A. Volkert Non applicable 497-500. (Published).
  • Guérin B, Tremblay S, Rodrigue S, Rousseau JA, Dumulon-Perreault V, Lecomte R, van Lier JE, Zyuzin A, van Lier EJ. (2010). Cyclotron production of 99mTc: an approach to the medical isotope crisis. J Nucl Med. 51 (4), 13N-6N. (Published).
  • Guérin B , Ait-Mohand S , Tremblay MC , Dumulon-Perreault V,* Fournier P,* Bénard F. (2010). Total solid-phase synthesis of NOTA-functionalized peptides for PET imaging. Organic letters 12 (2), 280-3. (Published).

Documents de travail

  • Véronique Dumulon-Perreault, Etienne Croteau, Samia Ait-Mohand, Jean-François Beaudoin, René Ouellet, Jacques A. Rousseau, Éric, Lavallée, Roger Lecomte, Éric Turcotte, Brigitte. Positron emitting tracers as alternatives to 99mTc-radiopharmaceuticals for pulmonary ventilation/perfusion scan.

Articles de conférence

  • H. Talebian, S. Ait-Mohand, L. Sanche, B Guérin. (2024). Development and in vitroEvaluation of a Novel 64Cu-NOTA-PSMA-Terpyridine Agent AgainstProstate Cancer. Conference Abstracts, (Published).
  • E. Molokova, R. Lebel, D. Sikpa, P. Ignatius G. Richard, S. Phoenix, B. Guerin, M. Lepage. (2024). Early imaging of radiotherapy induced neuroinflammation in a rat model of stereotactic radiosurgery. J. Nucl. Med., 242247. (Published).
  • J.-M. Beauregard, E. Rousseau, A. Zamanian, F. Saad, P. Richard, S. Probst, E. Lévesque, V. Castonguay, N. Marcoux, M. Lodde, D. Juneau, Z. Hamilou, J.-B. Lattouf, F.-A. Buteau, M. Pavic,J.-F. Castilloux, B. Neveu, G. Bouvet, C. Allard, A. Tétu, B. Guerin, F. Pouliot. (2024). Eligibility to PSMA-RLTbased on dual FDG/PSMA-PET: a subanalysis of the 3TMPO study. J. Nucl. Med., 241044. (Published).
  • A. Mirzaei, S. Ait-Mohand, E. Rousseau, B. Guérin. (2024). Enhanced Selectivity andAccumulation in Glioblastoma Cells Through Combining 64Cu-NOTA−TerpyridinePlatinum to cRGDfK Peptide. Conference Abstracts, (Published).
  • A. Dupuis, E. Rousseau, E. Turcotte, B. Guerin, G. Richard, E. Croteau, Y. Collin. (2024). Radiomic analysis of 68Ga-DOTATATE PET to characterize growth potential of neuroendocrine cancer lesions. J. Nucl. Med., 242257. (Published).
  • A. Zamanian, E. Rousseau, F.-A. Buteau, F. Arsenault, A. Beaulieu, G. April, G. Abikhzer, D. Juneau, N. Plouznikoff, E. Turcotte, C. Allard, S. Probst, P. Richard, F. Saad, B. Guerin, F. Pouliot, J.-M. Beauregard. (2024). The tumor sink effect onPSMA-PET/CT in metastatic prostate cancer and its implications for PSMA-RLT:insight from the 3TMPO study. J. Nucl. Med., 241300. (Published).
  • M. Paquette, S. Phoenix, E. Espinosa-Bentancourt, E. Lavallée, S. Dubreuil, B. Guerin, E. Turcotte. (2023). 18F-4FMFES-PET in ER+ lobular breast cancer. J. Nucl. Med., P1167. (Published).
  • M. Paquette, S. Ait-Mohand, A. Oweida, E Rousseau, B Guerin, E Turcotte. (2023). 64Cu-DOTHA2-FAPI-04 and FDG PET to monitornivolumab therapy in a HuPBMC-NCG melanoma mouse model. J. Nucl. Med., P1177. (Published).
  • B. Guerin, S. Ait-Mohand, V. Dumulon-Perreault, J. Rousseau1, O. Sarrhini, S. Tremblay, M. Maier, M.Salzmann. (2023). Development of a PET imaging agent for the detection of amyotrophic lateral sclerosis. EANM’23Abstract Book Congress Sep 9-13, 2023. Eur J Nucl Med Mol Imaging 50 (Suppl 1), 1–898 (2023). https://doi.org/10.1007/s00259-023-06333-x. Annual Congress of the European Association of Nuclear Medicine EANM’23. (Published).
  • J. Fernandez Fernandez, G. Sanchez-Delgado, S. Hogan-Lamarre, G. Richard, F. Frisch, S. Phoenix, M. Fortin, L. Bouffard, C. Noll, W. Mampuya, B. Guerin, E.E. Turcotte, J. Hoeks, P. Schrauwen, A. C. Carpentier, D.P. Blondin. (2023). Does myocardium andliver fractional uptake of circulating fatty acids change after consuming a mealin people with prediabetes? EANM’23 Abstract Book Congress Sep 9-13, 2023. EurJ Nucl Med Mol Imaging 50 (Suppl 1), 1–898 (2023). Annual Congress of the European Association of Nuclear Medicine EANM’23. (Published).
  • S. Gandy, E. L. Castranio, M. Varghese, E. Argyrousi, K. Tripathi, E. Bresnahan, D. Lerner, F. Garretti, H. Zhang, J. van de Loo, R. Talty, C. Glabe, E. Levy, M. Wang, B. Zhang, W. Lubell, B. Guerin, S. Rahimipour, D.L. Dickstein, O. Arancio, Mà. E. Ehrlich. (2023). Nonfibrillar Dutch mutant Aβ aggregates (oligomers) revealed by anti-prefibrillar oligomerantibody A11 and FITC-cyclic D,L-a-peptide imaging are associate with aging-relatedsynaptic dysfunction but cause no detectable inflammation. Conference Abstracts, (Published).
  • I. Ben-Salem, E. Croteau, V. Dumulon-Perreault, N. Saidi,O. Sarrhini, S. Ait-Mohand, O. Belissant, E. Turcotte, A.Oweida, B. Guerin, E. Rousseau;. (2023). Preclinical evaluation of 64Cu-DOTHA2-FAPI for PET Imaging of head and neck cancer. EANM’23 Abstract Book Congress Sep 9-13,2023. Eur J Nucl Med Mol Imaging 50 (Suppl 1), 1–898 (2023). https://doi.org/10.1007/s00259-023-06333-x. Eur J Nucl Med Mol Imaging, 1–898. (Published).
  • F. Pouliot, F. Saad, P. O. Richard, S. Probst, É. Rousseau, E. Levesque, V. Castonguay, N. Marcoux, M. Lodde, J.-B. Lattouf, F.-A. Buteau, D. Juneau, Z. Hamilou, M. Pavic, J.-F. Castilloux, A. Zamanian, G. Bouvet, A. Tetu, B. Guérin, J.-M. Beauregard. (2023). Prevalence ofintra-patient inter-metastatic heterogeneity in mCRPC patients based ontriple-tracer PET imaging: The 3TMPO study. J. Clin Oncol., 5033. (Published).
  • V. Dumulon-Perreault*, S. Ait-Mohand*, O. Sarrhini*, R. Mulamreddy, S. Vutla, K. Fernandes, W. D. Lubell, S. Rahimipour, B. Guérin;. (2022). Eur J Nucl Med Mol Imaging64Cu-Azacyclopeptide targeting soluble Aβ oligomers as an early Alzheimer’s diseasediagnostic PET tracer. (Suppl 1),1–751 (2022). https://doi.org/10.1007/s00259-022-05924-4. EANM’22 Congress. (Published).
  • E. Croteau, A. Huot-Daneault, R. Ouellet, C. Pouliot, J. Rousseau, E. Lavallee, E. E. Turcotte, E. Rousseau, B. Guérin**. (2022). Eur J Nucl Med Mol ImagingClinical validation of 99mTc-MDPand 99mTc-MIBI labeled with cyclotron-produced sodium 99mTcpertechnetate, an advantageous alternative to generator-produced pertechnetate. (Suppl 1),1–751 (2022). EANM’22 Congress. (Published).
  • I. Ben-Salem, E. Croteau1, V. Dumulon-Perreault, S. Ait-Mohand, O. Bélissant, E. Turcotte, A. Oweida, B. Guérin, E. Rousseau;. (2022). Eur J Nucl Med Mol ImagingUse of the fibroblast activation protein inhibitor 64CuDOTHA2-FAPIfor PET imaging of murine orthotopic head and neck cancer. (Suppl 1),1–751 (2022). https://doi.org/10.1007/s00259-022-05924-4. EANM’22 Congress. (Published).
  • F. Pouliot, F. Saad, P. Richard, E. Rousseau, S. Probst, E. Levesque, V. Castonguay, N. Marcoux, M. lodde, D. Juneau, Z. Hamilou, J. Lattouf, F. Buteau, M. Pavic, J. Castilloux, B. Neveu, G. Bouvet, A. Tetu, B. Guérin, J. Beauregard. Annals of Oncology (2022) 33 (suppl_7): S616-S652. (2022). FDG-positive/PSMA-negative PET lesion prevalence inmetastatic castration-resistant prostate cancer and its correlation with linesof systemic therapy: Results from the prospective 3TMPO imaging study. ESMO Targeted Anticancer Therapies Congress. (Published).
  • M.-C. Milot, V. Dumulon-Perreault, S. Ait-Mohand, P. Richard, E. Rousseau and B. Guerin. (2022). J. Nucl. MedIn the search of new chelator to improve prostatecancer radiotheranostic, the study of 64Cu/177Lu-CT-PCTA-PSMA. . , 63 (supplement 2) 2477;. Society of Nuclear Medicine Annual Meeting, SNMMI 2022. (Published).
  • M.-C. Milot*, O. Belissant Benesty*, V. Dumulon-Perreault,* S. Ait-Mohand*, S.Geha, P. Richard, E. Rousseau and B. Guerin**. (2022). J. Nucl. MedThe journey to a novel theranostic for prostate cancer :the preclinical study of 64Cu-DOTHA2-PSMA. . , 63 (supplement 2) 4025; . Society of Nuclear Medicine Annual Meeting, SNMMI 2022. (Published).
  • M.-C. Milot*, P. O. Richard, É. Rousseau, B. Guérin**. (2021). 64Cu-DOTHA2-PSMA's preclinicalstudy for molecular radiation therapy and its normal tissue toxicity and dosimetry. RRS Annual meeting. Virtual Meeting. (Published).
  • M. Khosravifarsani, S. Ait-mohand, B. Paquette, L. Sanche, B. Guérin. (2021). Development of low energy electron sources as novel chemo-radio therapeutic (CRT) agents: in-vitro study of 64Cu/NOTA-terpyridine platinum in colorectal cancer cell. POSMOL 2021 XXII International Symposium on Electron-Molecule Collisions and Swarms Virtual Meeting. (Published).
  • El-Husseini, A.;Mulamreddy, R;. Vutla, S.; Chauhan, P.; Habashi, M.; Richman, M.; Chingle, R.M.; Guérin, B; Rahimipour, S.; Lubell, W.D. (2021). Synthesis and anti-amyloid activity of azacyclopeptides. 51st IUPAC General Assembly, 48th World Chemistry Conference, 104th Canadian Chemistry Conference and Exhibition. (Published).
  • M. Khosravifarsani, S. Ait-mohand, B. Paquette, L. Sanche, B. Guérin. (2021). The cytotoxic effect of64Cu/NOTA-terpyridine platinum conjugate, as a novel chemoradiotherapyagent. The 1st International Electronic Conference on Cancers: Exploiting Cancer Vulnerability by Targeting the DNA Damage Response Congress Virtual. (Published).
  • M.-C. Milot, O. Bélissant, V. Dumulon-Perreault, S. Ait-Mohand, P. O. Richard, É. Rousseau, B. Guérin. (2021). Theranostic 64Cu-DOTHA2-PSMAfor metastatic prostate cancer treatment, a preclinical study. eSRS Society of Radiopharmaceutical Sciences. Virtual Meeting. (Published).
  • A. Huwaidi, B. Kumari, G. Robert, B. Guérin, J. R. Wagner, Léon Sanche. (2021). X-ray irradiation of DNA in the presence gold nanoparticles promotes lowenergy electron induced DNA damage: LC-MS/MS study. POSMOL 2021 XXII International Symposium on Electron-Molecule Collisions and Swarms Virtual Meeting. (Published).
  • M. Paquette, E. Espinosa-Bentancourt, É. Lavallée, S. Phoenix, B. Guérin, É. E. Turcotte. (2020). 4FMFES and FDG-PETimaging in uterine cancer patients: preliminary assessment. EANM 2020 Congress Virtual Meeting,. (Published).
  • O. Belissant Benesty, V. Dumulon-Perreault, S. Ait-mohand, M.-C. Milot, S. Tremblay, J.-F. Beaudoin, E. Rousseau, E. Turcotte, J.-M. Beauregard, F. Pouliot, B. Guérin. (2020). 68Ga-PSMA-617:cellular evidence supporting later acquisition of PET images. Society of Nuclear Medicine Annual Meeting, SNMMI 2020. Virtual Edition J Nucl Med. 2020, 61:1226. (Published).
  • O. Belissant Benesty, V. Dumulon-Perreault, S. Ait-mohand, S. Tremblay, J.-F. Beaudoin, E. Rousseau, E. Turcotte, J.-M. Beauregard, F. Pouliot, B. Guérin. (2020). 68Ga-PSMA-617: from gallium production by cyclotron to clinical application. Society of Nuclear Medicine Annual Meeting, SNMMI 2020. Virtual Edition J Nucl Med. 2020, 61:96. (Published).
  • M.-C. Milot, O. Belissant Benesty, V. Dumulon-Perreault, S. Ait-mohand, E. Rousseau, P. Richard, B. Guérin. (2020). A stronger chelation for a superior theranostic : the preclinical study of 64Cu-DOTHA2-PSMAin prostate cancer animal model. Society of Nuclear Medicine Annual Meeting, SNMMI 2020. Virtual Edition J Nucl Med. 2020, 61:1200. (Published).
  • J.-M. Beauregard, V. Forget, A. Desy, O. Belissant Benesty, F.-A. Buteau, A. Beaulieu, F. Arsenault, G. April, G. Bouvet, B. Guérin, E. Turcotte. (2020). Quantitative 177Lu-SPECT(QSPECT) during second cycle predicts 68Ga-octreotate-PET/CTmolecular response to 177Lu-octreotate PRRT. Society of Nuclear Medicine Annual Meeting, SNMMI 2020. Virtual Edition J Nucl Med,2020, 61:411. (Published).
  • M. Paquette, E. Espinosa-Bentancourt, É. Lavallée, S. Phoenix, B. Guérin, É. E. Turcotte. (2020). Reducing abdominalbackground in 4FMFES-PET using intestinal peristalsis inhibitors: atranslational study. EANM 2020 Congress Virtual Meeting. (Published).
  • M. Paquette, E. Espinosa-Bentancourt, É. Lavallée, S. Phoenix, B. Guérin, É. E. Turcotte. (2020). Reducing abdominal background in 4FMFES-PET usingintestinal peristalsis inhibitors: a translational study. EANM 2020 Congress. (Published).
  • S. Tremblay, J.-F. Beaudoin, S. Ait-Mohand, A Alnhawi, C. Pouliot, B. Guérin. (2020). S. Tremblay, J.-F. Beaudoin, S. Ait-Mohand, , C. Pouliot, B. Guérin. Symposium imaginez l’imagerie Congress Virtual Meeting. (Published).
  • M.-C. Milot, O. Bélissant, V. Dumulon-Perreault, S. Ait-Mohand, P. O. Richard, É. Rousseau, B. Guérin. (2020). Theranostic 64Cu-DOTHA2-PSMAfor metastatic prostate cancer treatment, a preclinical study. EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium. (Published).
  • M.-C. Milot, O. Bélissant, V. Dumulon-Perreault, S. Ait-Mohand, P. O. Richard, É. Rousseau, B. Guérin. (2020). Theranostic 64Cu-DOTHA2-PSMAfor preclinical imaging of prostate cancer. Radiation Research Society’66th Annual Meeting -Virtuel Edition. (Published).
  • M. Khosravifarsani, S. Ait-mohand, L. Sanche B. Guérin. (2020). The synthesis andcytotoxicity of 64Cu/NOTA-terpyridine platinum conjugate, as a noveltheranostic agent. International Symposium on Trends in Radiopharmaceuticals (ISTR-2019). (Published).
  • M. Paquette, S. Phoenix, B. Guérin, É. E. Turcotte. (2020). Time after synthesisdoes not affect 4FMFES biodistribution and PET imaging. EANM 2020 Congress, Virtual Meeting,. (Published).
  • M. Paquette, E. Lavallée, S. Phoenix, H. Senta, R. Lecomte, B. Guerin, E. Turcotte. (2019). 4FMFES-PET in ER+ lobular breast cancer: revealing what FDG-PET could not. Society of Nuclear Medicine Annual Meeting, SNMMI 2018 J Nucl Med 2019 60:1227. (Published).
  • M. Paquette, S. Phoenix, R. Lecomte, B. Guerin, E. Turcotte. (2019). 4FMFES and FDG-PET of a ER+ uterine cancer mousexenograft model. Society of Nuclear Medicine Annual Meeting, SNMMI 2018 J Nucl Med 2019 60:1418. (Published).
  • S. Beaudoin, S, Tremblay, S. Ait-mohand, J. Leyton, B. Guerin. (2019). A new PET imaging agent for monitoring HER2 status using Trastuzumabantibody conjugated with a novel 89Zr-chelator. Society of Nuclear Medicine Annual Meeting, SNMMI 2018 J Nucl Med 2019 60:1009. (Published).
  • J.-M. Beauregard, P. Cadieux, F.-A. Buteau, A. Beaulieu, B. Guérin, E. Turcotte. (2019). Development ofTheranostic Response Criteria In Solid Tumors (THERCIST) and tumor burdenquantification methods for 68Ga-PET/CT and 177Lu-QSPECT/CT. Society of Nuclear Medicine Annual Meeting, SNMMI 2018 J Nucl Med 2019 60:626. (Published).
  • L. Dery, G. Charette, L. Sanche, B. Guérin. D. Fortin. 2nd price, poster presentation to L. Dery. (2019). Gliotrap: un nouveau traitement contre les tumeurscérébrales primaires. Symposium de la recherche sur le cancer. (Published).
  • E. Croteau, E. Rousseau, P. Prud'Homme, S. Cunnane, V. Dumulon-Perreault, M. Archambault, O. Sarrhini, M.-A. Richard, S. Tremblay, B. Guerin, R. Lecomte. (2019). Heart ketone uptakereserve in diabetic ZDF rats with an acute ketone ester supplementation: a [11C]-acetoacetaterest-stress study. Society of Nuclear Medicine Annual Meeting, SNMMI 2018 J Nucl Med 2019 60:36. (Published).
  • M. Khosravifarsani, S. Ait-Mohand, L. Sanche, B. Guérin. (2019). In-vitro cytotoxiceffect of 64Cu/NOTA-terpyridine platinum complex, as a novel chemoradiationtherapy (CRT) agent. Symposium de la recherche sur le cancer. (Revision Requested).
  • M. Khosravifarsani, S. Ait-mohand, L. Sanche, B. Guérin. (2019). In-vitro cytotoxic effect of 64Cu/NOTA-terpyridineplatinum conjugate, as a novel theranostic agent. Society of Nuclear Medicine Annual Meeting, SNMMI 2018 J Nucl Med 2019 60:1615. (Published).
  • A. Alnahwi, S. Tremblay, S. Ait-Mohand, J.-F. Beaudoin, B. Guerin. (2019). Large-scale routineproduction of 68Ga using 68Zn-pressed target. Society of Nuclear Medicine Annual Meeting, SNMMI 2018 J Nucl Med 2019 60:634. (Published).
  • S. Kanh Ali, S. Ait-Mohand, V. Dumulon-Perreault, B. Guérin. Best poster presentation to S. Kanh Ali. (2019). Le 68Ga-4HMSA, un traceur TEP pourl’imagerie de l’inflammation ?. Symposium de la recherche sur le cancer. (Published).
  • J.-M. Beauregard, F.-A. Buteau, A. Beaulieu, F. Arsenault, M. Del Prete, N. Lafrenière, E. Turcotte, B. Guérin. (2019). Planning ofpersonalized 177Lu-octreotate PRRT with 68Ga-octreotate-PET/CT:the tumor sink effect and the renal uptake as predictors of renal dosimetry. Society of Nuclear Medicine Annual Meeting, SNMMI 2018 J Nucl Med 2019 60:628. (Published).
  • J.-F. Beaudoin, S. Tremblay, A. Alnahwi, B. Guerin. (2019). Target carrier anddissolution system for facilitating end-to-end in-vault cyclotron production ofradiometals in large quantities. Society of Nuclear Medicine Annual Meeting, SNMMI 2018 J Nucl Med 2019 60:1162. (Published).
  • V. Dumulon-Perreault, S. Ait-mohand, S. Tremblay, E. Rousseau, E. Turcotte, J.-M. Beauregard, F. Pouliot, B. Guerin. (2019). Validation of 68Ga-4HMSA-PSMA,a novel PSMA radioligand for PET Imaging of Prostate Cancer. Society of Nuclear Medicine Annual Meeting, SNMMI 2018 J Nucl Med 2019 60:1044. (Published).
  • G. Charest*, S. Ait-Mohand*, O. Sarrhini, J. Rousseau, D. Stanimirovic, R. Hutchison, D. Fortin and B. Guérin. (2018). Measurement of blood brain barrier transport using radiolabeled antibodies. ESRR’18 – 19th European Symposium on Radiopharmacy and Radiopharmaceuticals. (Published).
  • G. Charest*, S. Ait-Mohand*, O. Sarrhini, J. Rousseau, D. Stanimirovic, R. Hutchison, D. Fortin and B. Guérin. (2018). Radiolabeled antibodiesto validate blood brain barrier penetration. Society of Nuclear Medicine Annual Meeting, SNMMI 2018. (Published).
  • V. Dumulon-Perreault, S. Tremblay, J.-F, Rousseau, S. Ait-Mohand, E. Rousseau, E. Turcotte, J.-M. Beauregard, F. Pouliot, B. Guerin. (2018). Validation of [68Ga]-Ga-DOTA-TATE using 68Gaproduced by cyclotron. Society of Nuclear Medicine Annual Meeting, SNMMI 2018. (Published).
  • A. H. Alnahwi*, S. Tremblay*, B. Guérin. (2017). 89Zr production via the 89Y(p,n)89Zrreaction using pressed target. 100th Canadian Chemistry Conference and Exhibition. Symposium in the Biological and Medicinal Chemistry Division. (Published).
  • M. Paquette*, V. Dumulon-Perreault*, S. Ait-Mohand*, B. Guérin. (2017). A New 64Cu-Labeled,Metabolic-Resistant Peptide with Nanomolar Affinity for NPY-Y1R for BreastCancer Targeting. EANM’17. (Published).
  • M. Paquette*, S. Ait-Mohand*, V. Dumulon-Perreault, F. Bénard, B. Guérin. (2017). A Novel 64Cu/NOTA-labeled Peptide with High Metabolic-resistance and NPY-Y1R Affinity. 100th Canadian Chemistry Conference and Exhibition. Symposium in the Biological and Medicinal Chemistry Division. (Published).
  • M. Paquette*, S. Beaudoin*, S. Phoenix*, L. Fafard-Couture, É. E. Turcotte, B. Guérin, R. Lecomte, J. V. Leyton. (2017). A Successive Triple PET Tracer Approach to Characterize ER and HER2 Status In Vivo in a Breast Cancer Mouse Xenograft Model. EANM’17. (Published).
  • B Guérin, M Savard, V Dumulon-Perreault, C Dubuc, S. Ait-Mohand*, F Gobeil Jr. (2017). A new 64Cu-radiolabeledpeptide conjugate for kinin B1R positive tumors. 22nd International Symposium on Radiopharmaceutical Sciences (ISRS 2017). (Published).
  • G. Charest*, O. Sarrhini, D. Fortin, D. Stanimirovic, R. Gabathuler, B. Guérin. (2017). Antibody-based PET imaging of brain cancer cells infiltration.SNO-SCIDOT joint conference ontherapeutic delivery to the CNS. SNO-SCIDOT joint conference on therapeutic delivery to the CNS. (Published).
  • B. Guérin, R. Ouellet*, S. Tremblay*. (2017). A simple method for the purification of Technetium-99m produced by cyclotron and the recycling of molybdenum. 22nd International Symposium on Radiopharmaceutical Sciences (ISRS 2017). (Published).
  • M. Paquette*, É. Lavallée, S. Phoenix*, H. Senta, B. Guérin, J. E. van Lier, R. Lecomte, É. E. Turcotte. (2017). Combined FDG and 4FMFES PET Imaging in ER+ Breast Cancer Patients for Improved Diagnostic andPrognostic Value. EANM’17. (Published).
  • M. Paquette*, S. Phoenix*, J. A. Rousseau, O. Sarrhini, B. Guérin, É. E. Turcotte, R. Lecomte. (2017). Cross-Species Physiological Assessment of Brain Estrogen Receptor Expression Using 4FMFES PET Imaging. EANM’17. (Published).
  • S. Phoenix*, S. Tremblay*, S. Ait-Mohand*, R. Ouellet*, P.Thibault, H. Senta, L. Caouette and B. Guérin. (2017). Gallium-68 DOTATATE Production with an Automated Synthesis System. 100th Canadian Chemistry Conference and Exhibition. Symposium in the Biological and Medicinal Chemistry Division. (Published).
  • A. H. Alnahwi*, S. Tremblay*, B. Guérin. (2017). Improved production yield, processing using cassette-based module and specific activity of Zirconium-89. Journée scientifique CANCER - INFLAMMATION – DOULEUR. (Published).
  • A. Alnahwi*, S. Tremblay* and B. Guerin. (2017). J. Nucl. Med. Improved production yield, processing and specific activity of 89Zr. 2017 58:335. Society of Nuclear Medicine Annual Meeting, SNMMI 2017. (Published).
  • A. Alnahwi*, S. Ait-mohand*, V. Dumulon-Perreault*, and B. Guerin. (2017). N-Radiolabeling and validation of a new acyclicchelator bearing hydroxy--methyl succinamide pendant arms for Zirconium-89 radionuclide, superior performance in comparison with DFO. 2017 58:67. Society of Nuclear Medicine Annual Meeting, SNMMI 2017. (Published).
  • A. H. Alnahwi*, S. Ait-mohand*, V. Dumulon-Perreault*, B. Guérin. (2017). NA new acyclic chelator bearing -hydroxy--methyl succinamide pendant arms for Zirconium-89 radionuclide: Radiolabeling and validation. Journée scientifique CANCER - INFLAMMATION – DOULEUR. (Published).
  • S. Aït-Mohand*, V. Dumulon-Perreault*, B. Guérin. (2017). NSuperior performance of a new acyclic chelator bearing -hydrox--methyl succinamide pendant arms, 4HMSA, in comparison with DOTA and NOTA for 68Ga PET. May 1, 2017 vol. 58:671. Society of Nuclear Medicine Annual Meeting, SNMMI 2017. (Published).
  • B. Guérin, S. Aït-Mohand*, A. Alnahwi*, V. Dumulon-Perreault*. (2017). Novel Acyclic Chelatorsfor 89Zr and 68Ga. ESRR’18 – 19th European Symposium on Radiopharmacy and Radiopharmaceuticals. (Published).
  • C. Zhang, J. Pan, K.-S. Lin, J. Zeisler, B. Guerin, and F. Benard. (2017). Stabilizing truncated peptides targeting the neuropeptide Y1 receptor for cancer imaging. JNucl Med 2017 58:693. Society of Nuclear Medicine Annual Meeting, SNMMI 2017,. (Published).
  • M. Paquette*, É. Lavallée, S. Phoenix*, H. Senta, J. E. van Lier, R. Lecomte, B. Guérin, É. E. Turcotte. (2017). Successful Diagnosis ofa CT-Negative, Bone Scintigraphy-Negative and FDG-PET-Negative Metastatic Recurrence Case Using ER-Targeting 4FMFES-PET. EANM’17. (Published).
  • N. Mansour*, M. Paquette*, S. Ait-Mohand*, V. Dumulon-Perreault*, R. Lecomte, B. Guérin. (2016). : Novel RadiolabeledPeptide for PET Imaging of Prostate Cancer64Cu-DOTHA2-PEG-RM26. Oral presentation given by B. Guérin. ESRR’16 – 18th European Symposium on Radiopharmacy and Radiopharmaceuticals. (Published).
  • S. Ait-Mohand*, V. Dumulon-Perreault*, B. Guérin. (2016). A new NPY-Y1R targeting peptide for breast cancer PET imaging. Oral presentation given by Guerin. ESRR’16 – 18th European Symposium on Radiopharmacy and Radiopharmaceuticals. (Published).
  • S. Osati*, M. Paquette*, S. Beaudoin*, H. Ali*, F. Marques, B. Guérin, J.V. Leyton and J. E. van Lier. (2016). BODIPY-estradiol conjugates as multi-modality tumor imaging agents. ESRR’16 – 18th European Symposium on Radiopharmacy and Radiopharmaceuticals. (Published).
  • M Paquette*, S Beaudoin*, L Fafard-Couture, L-G Vilera-Perez, N Ekindi-Ndongo, A Lopez, R Lecomte, R Sabbagh, B Guerin, and J Leyton. (2016). ChAcNLS-A14, a novel antibody-conjugate PET tracer for targeting human IL-5R?-positive muscle invasive bladder cancer. J Nucl Med 2016, 57:52. Society of Nuclear Medicine Annual Meeting, SNMMI 2016. (Published).
  • L. Fafard-Couture, S. Osati*, S. Beaudoin*, V. Dumoulon-Perreault*, R. Lebel, M. Lepage, B. Guerin, J. van Lier, and J. Leyton. (2016). ChAcNLS-A14-B105, a novel photodynamic imaging agent for detection of muscle invasive bladder cancer. AACR Annual Meeting 2016. (Published).
  • S. Ait-Mohand*, V. Dumulon-Perreault*, F. Benard B. Guérin. (2016). Design optimization of a new 64Cu/NOTA truncated NPY analog with improved stability and Y1 affinity, the first step toward successful breast cancer PET Imaging. J Nucl Med, 2016, 57:1076. Society of Nuclear Medicine Annual Meeting, SNMMI 2016,. (Published).
  • C Zhang, J Pan, K-S Lin, I Dude, J Lau, H Merkens, S Jenni, B Guerin, and F Benard. (2016). Improved 68Ga-labelled truncated peptides targeting the neuropeptide Y1 receptor for cancer imaging by positron emission tomography. Society of Nuclear Medicine Annual Meeting, SNMMI 2016. (Published).
  • DP Blondin, B Guérin, EE Turcotte, D Richard, F Haman , AC Carpentier. (2016). Inhibition of intracellular triglyceride lipolysis significantly impairs BAT oxidative metabolism in humans. Keystone Symposia on Molecular and Cellular Biology. (Published).
  • M Paquette*, S Beaudoin*, L Fafard-Couture, A Lopez, R Lecomte, B Guerin, and J Leyton. (2016). Novel 64Cu-labeled antibody-conjugates designed to evade the endosomal-lysosomal pathway for increased intracellular radio-accumulation in target IL-5R?-positive muscle invasive bladder cancer cells. J Nucl Med 2016, 57:391. Society of Nuclear Medicine Annual Meeting, SNMMI 2016. (Published).
  • G Tremblay*, S Aït-Mohand*, R Ouellet* and B Guérin. (2016). Novel syntheticapproach for one-pot F-18 labeling of unprotected peptides for PET imaging. Journée Phare 2016, Congrès québécois en sciences de la santé. (Published).
  • M Paquette*, E Lavallee, S Phoenix, H Senta, B Guerin, J van Lier, R Lecomte, and E Turcotte. (2016). Ongoing Phase II Trial Comparing 4FMFES and FES Estrogen-Receptor PET Tracers in Breast CancerPatients: an Update. J Nucl Med 2016, 57:567. Society of Nuclear Medicine Annual Meeting, SNMMI 2016,. (Published).
  • A Pirisedigh*, Y Dory, L Gendron, B Guerin. (2016). Preparation and evaluation of a series of 19F-enkephalin analogues; the first step in the design of potent and selective 18F-labeled PET tracers for delta opioid receptor imaging. 252 nd ACS National Meeting. (Published).
  • F Gobeil Jr, M Savard, V Dumulon-Perreault*, C Dubuc*, E Croteau, and B Guerin. (2016). Theranostic potential of a new [64Cu]-radiolabeled R-954 conjugate for kinin B1R positive tumors. J Nucl Med 2016, 57:1164. Society of Nuclear Medicine Annual Meeting, SNMMI 2016. (Published).
  • G Tremblay*, S Aït-Mohand*, R Ouellet* and B Guérin. (2015). .Novel synthetic approach for one-pot F-18 labeling of unprotected peptides for PET imaging. 26th Québec/Ontario Mini-Symposium in Bioorganic and Organic Chemistry. (Published).
  • M. Paquette*, S. Beaudoin*, L. Couture-Fafard, L.Vilera, N, Ekindy, R. Sabbagh, R. Lecomte, B. Guérin, A. Lopez, and J. V. Leyton. (2015). A Novel Antibody-Conjugate Design To Exploit Internalization and Trafficking of Interleukin-5 Receptor ?-subunit– Implications For More Effective Tumor Targeting. CRCL 2015 (2nd International Symposium of the Cancer Research Center of Lyon). (Accepted).
  • S. Osati*, H. Ali*, M. Paquette*, B.Guérin and J. E. van Lier. (2015). BODIPY- Estradiol Conjugates for Fluorescence Imaging of Breast Cancer. European Society for Photobiology 2015 Congress. (Accepted).
  • N. Mansour*, M. Paquette*, S. Ait-Mohand*, B. Guerin. (2015). Biological evaluation of 64Cu-radiolabeled gastrin-releasing peptide receptors antagonist conjugated to DOTHA2 a new bifunctional chelator bearing hydroxamic acid arms. 2nd International Conference on Prostate Cancer and Treatment. (Accepted).
  • A. Pirisedigh*, Y. Dory, L. Gendron, B. Guérin. (2015). Design, Synthesis and Evaluation of Selective 19F-Enkephalin Analogs; A First Step in the Development of PET Tracers for DOP Imaging. 26th Québec/Ontario Mini-Symposium in Bioorganic and Organic Chemistry. (Accepted).
  • É. Croteau*, C.-A. Castellano, S. Tremblay, B. Guérin, L. De Beaumont, S.C. Cunnane. (2015). Imagerie cérébrale de l’activité métabolique et de la protéine ?-amyloïde chez d’anciens athlètes universitaires ayant subi un traumatisme craniocérébral léger. Journée scientifique 2015. (Published).
  • S. V. Selivanova*, É. Lavallée, O. Sarrihni, B. Guérin, É. Turcotte, R. Lecomte. (2015). Investigation of Image Quality with Sodium Pertechnetate 99mTc Produced by Cyclotron. EANM'15 - Annual Congress of the European Association of Nuclear Medicine. (Published).
  • C. Zhang, J. Pan, J. Lau, N. Colpo, S. Jenni, S. Park, B. Guerin, K.Lin, F. Bénard. (2015). In vitro and in vivo evaluation of a novel 68Ga-labeled BVD15 analogue for neuropeptide Y1 receptor imaging with positron emission tomography. WMIC 2015, 8th Annual World Molecular Imaging Congress. (Published).
  • F. Gobeil jr, M. Savard, C. Dubuc, J. Côté,, V. Dumulon-Perreault*, M. Paquette*, É.Croteau, S. Ait-Mohand*, B. Guérin. (2015). Novel Kinin-Based Analogues as Potential BBB-Penetration Enhancers for Delivery of Chemotherapy and as New Theranostic Agents for Imaging and Treatment of Malignant Brain Cancer. Kinin 2015 - International Meeting on Kinin System and Peptide Receptors. (Published).
  • G. Tremblay*, S. Aït-Mohand*, R. Ouellet*, B. Guérin. (2015). Novel Synthetic approach for one-pot 18F radiolabeling of unprotected peptides for PET imaging. Journée scientifique 2015. (Accepted).
  • G. Tremblay*, S. Ait-Mohand*, R. Ouellet, and B. Guerin. (2015). Novel synthetic approachfor one-pot F-18 labeling of unprotected peptides for PET imaging. J NuclMed 2015 56:221. Society of Nuclear Medicine Annual Meeting, SNMMI 2015,. (Accepted).
  • F Couture, K Ly, C Levesque, A Kwiatkowska, R Desjardins, B Guérin, R Day. (2015). PACE4-dependent cellular uptake and retention of the Multi-Leucine peptide inhibitor into cancer cells. AACR Annual Meeting 2015. (Published).
  • S. Selivanova*, É. Lavallée, H. Senta, L. Caouette, A. Zyuzin, A. McEwan, J. van Lier, B. Guerin, R. Lecomte, and É. Turcotte. (2015). Phase I clinical trial using sodium pertechnetate 99mTc produced by medium-energy cyclotron. J Nucl Med 2015 56:475. Society of Nuclear Medicine Annual Meeting, SNMMI 2015. (Accepted).
  • M. Paquette*, L. Fafard-Couture, S. Beaudoin, B. Guérin, J. Leyton. (2015). Évaluation préliminaire in vivo par imagerie TEP d'un anticorps-NLS-acide cholique marqué au cuivre-64 et ciblant IL5-R? dans un modèle de cancer de la vessie. Journée scientifique 2015. (Accepted).
  • A. Rondeau*, S. Beaudoin*, B. Guerin, M. Bentourkia, and J. V. Leyton. (2014). A novel delivery system for enhanced cellular accumulation inside IL-3Ra+ leukemic stem cells using functionalized 7G3 antibody. Symposium Imaginez l'imagerie. (Accepted).
  • S. V. Selivanova, É. Lavallée, H. Senta, J. Sader, E.J. van Lier, A. Zyuzin, J. E. van Lier, B. Guérin, R. Lecomte, É. Turcotte. (2014). Clinical quality sodium pertechnetate Tc-99m is reached with cyclotron at 24 MeV. EANM Congress 2014. (Published).
  • G. Tremblay*, S. Ait-Mohand*, C. Denis*, M. Paquette* and B. Guérin. (2014). DOTHA2 and NOTHA2, New Chelates for Highly Efficient Cu-64 Radiolabeling. Journée Phare 2014. (Accepted).
  • G. Tremblay*, S. Ait-Mohand*, C. Denis*, M. Paquette* and B. Guérin. (2014). DOTHA2 and NOTHA2, New Chelates for Highly Efficient Cu-64 Radiolabeling. Symposium Imaginez l'imagerie. (Published).
  • S. Ait-Mohand*, C. Denis*, G. Tremblay*, M. Paquette* and B. Guérin. (2014). DOTHA2 and NOTHA2—New Chelates for Highly Efficient Cu-64 Radiolabeling. TERACHEM 2014 Symposium. (Accepted).
  • Blanchette M, Gascon S, Tremblay S*, Tremblay L, Guérin B, Lepage M, Lecomte R, Fortin D. (2014). Does Osmotic blood-brain Barrier Disruption allows efflux pump substrates delivery to the tumor and CNS?. 19th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology. (Submitted).
  • N. Mansour*, V. Dumulon-Perreault*, L. Matei*, S. Ait-Mohand*, B. Guerin. (2014). Impact des espaceurs sur la biodistribution in vivo d'antagonistes de GRPR marqués au 64Cu/NOTA. 56e réunion annuelle du CRCQ. (Accepted).
  • S. V. Selivanova*, E. Lavallée, J. Sader, E. J. van Lier, A. Zyuzin, J. E. van Lier, É. Turcotte, R. Lecomte, B. Guérin. (2014). Isotopic purity of 100Mo targetis paramount for cyclotron production of clinical quality 99mTc. American Chemical Society Meeting. (Accepted).
  • C. Denis*, S. Ait-Mohand*, N. Mansour*, G. Tremblay*, B. Guérin. (2014). Le 64Cu , un radionucléide à visée théranostique pour le cancer. Symposium de la recherche sur le cancer. (Published).
  • F.Couture*, C. Levesque, V. Dumulon-Perreault, S. Ait-Mohand*, F. D’Anjou, B. Guérin, R. Day. (2014). Molecular imaging of prostate cancer using an engineered PACE4 radiolabelled peptide inhibitor. Symposium Imaginez l'imagerie. (Accepted).
  • A.Zyuzin, J. Sader, E. Jenei, S. Tremblay*, P. Thibault, B. Guérin. (2014). New Targetry Possibilities from the TR-24. 15Th Internanional Workshop on targetry and target chemistry. 15Th Internanional Workshop on targetry and target chemistry. (Accepted).
  • G. Tremblay*, S. Ait-Mohand* et B. Guérin. (2014). Novel synthetic approaches to 18F radiolabeling of gastrin receptor targeting peptides for breast and prostate cancer PET imaging. Journée scientifique de la faculté de médecine et des sciences de la santé. (Published).
  • G. Tremblay*, S. Ait-Mohand* et B. Guérin. (2014). Novel synthetic approaches to 18F radiolabeling of gastrin receptor targeting peptides for breast and prostate cancer PET imaging. Symposium de la recherche sur le cancer. (Published).
  • G. Tremblay*, S. Ait-Mohand* et B. Guérin. (2014). Novel synthetic approaches to 18F radiolabeling of gastrin receptor targeting peptides for breast and prostate cancer PET imaging. 56e réunion annuelle du CRCQ. (Accepted).
  • C. Levesque, F. Couture, S. Ait-Mohand*, B. Guérin, R. Day. (2014). PACE4 Inhibitors and Their Peptidomimetic Analogs Block Prostate Cancer Tumor Progression Through Quiescence Induction, Increased Apoptosis and Impaired Neovascularisation. Gordon Research Conference on Protein Processing, Trafficking and Secretions. (Published).
  • S. Ait-Mohand*, C. Denis*, G. Tremblay*, M. Paquette*, B. Guérin. (2014). Synthesis and Evaluation of DOTHA2 and NOTHA2 Bifunctional Chelators Bearing N-Methyl-Hydroxamic Acid Arms. 97th Canadian Chemistry Conference and Exhibition. (Published).
  • G. Tremblay*, S. Ait-Mohand*, C. Denis*, B. Guérin. (2014). Synthesis and evaluation of DOTHA2 and NODHA2 bifunctional chelators bearing methyl-hydroxamic acid arms. Society of Nuclear Medicine Annual Meeting. (Published).
  • V. Dumulon-Perreault*, S. Ait-Mohand*, L. Matei*,P. Fournier*, J.F Beaudoin, F. Benard,B. Guerin. (2013). 64Cu-labeled GRPR agonist and antagonist in prostate cancer PET imaging. SNMMI 2013, Vancouver, BC, Canada, June 8-12, 2013. (Published).
  • S. V. Selivanova*, L. Matei*, V. Dumulon-Perreault*, J. Rousseau, É. Turcotte, B. Guérin R. Lecomte. (2013). 99mTc-Pertechnetate Production Using a Cyclotron: Considerations for Patient Dosimetry and Personnel Radiation Protection. CRPA Conference, Sherbrooke, Quebec, May 26 – 30. (Published).
  • S. Selivanova*, L. Matei*, R. Lecomte, J. van Lier, E. Turcotte, J. Sader, E. van Lier, A. Zyuzin, University of Alberta, B. Guérin. (2013). 99mTc-Pertechnetate production using a medium-energy cyclotron. SNMMI 2013, Vancouver, BC, Canada, June 8-12, 2013. (Published).
  • S. Selivanova*, L. Matei*, V. Dumulon-Perreault*, J. Rousseau, J. Sader, E. J. van Lier, A. Zyuzin, J. E. van Lier, É. Turcotte, R. Lecomte, B. Guérin. (2013). 99mTc-pertechnetate manufacturing using a medium-energy cyclotron: from target irradiation to quality control. Radiometals 2013, Santa Rosa, California, USA, June 13-16, 2013. (Published).
  • J. Fortin*, M.-O. Benoit Biancamano, B. Guérin. (2013). Caractérisation du rôle de l'amyline (IAPP) dans le diabète de type 2 et les tumeurs des îlots pancréatiques. Congrès de l’ACFAS, Université Laval, Qc, Canada, May 7, 2013. (Accepted).
  • A. Zyuzin, E. van Lier, J. Sader, B. Guerin, R. Lecomte, M. Toussaint, E Turcotte, D Abrams, A McEwan, John Wilson, S. McQuarrie, S. Jakeway. (2013). Cyclotron production of 99mTc in Canada. 245th ACS National Meeting, New Orleans, LA. (Published).
  • M. Pourghiasian, J. A.Inkster, N. Hundal, B. Guerin, T. Ruth, K.S. Lin, F. Benard. (2013). PEGylated F-18 labeled bombesin derivatives for improved GRP receptor imaging in prostate cancer. SNMMI 2013, Vancouver, BC, Canada, June 8-12, 2013. (Published).
  • P. Fournier*, V. Dumulon-Perreault*, S. Ait-Mohand*, R. Langlois, F. Benard, R. Lecomte, B. Guerin. (2012). Comparative study of GRPR-targeting monomer and dimers for prostate cancer PET imaging. SNM Annual Meeting, Miami, Fl, June 9-13, 2012.J Nucl Med. 2012; 53 (Supplement 1): 1646. (Published).
  • E. Turcotte, M. Paquette*, E. Lavallée, R. Langlois, S. Dubreuil, H. Senta, R. Lecomte, B. Guerin, F. Benard, J. Van Lier. (2012). Comparison of 4FMFES-PET with FES-PET in a phase II trial to detect estrogen receptor-positive breast cancer: Preliminary results. SNM Annual Meeting, Miami, Fl, June 9-13, 2012. J Nucl Med. 2012; 53 (Supplement 1):281. (Published).
  • P. Fournier*, V. Dumulon-Perreault*, S. Ait-Mohand*, R. Lecomte, F. Bénard and B. Guérin. (2012). Labelling of a novel peptide for GRPR breast and prostate tumor PET imaging with 64Cu and 68Ga, an in vitro and in vivo comparative study. World Molecular Imaging Congress (WMIC 2012). (Published).
  • V. Dumulon-Perreault*, E. Croteau, S. Ait-Mohand*, R. Ouellet*, J. Rousseau, J.-F. Beaudoin, J.-F. Gagnon, R. Lecomte, E. Turcotte, B. Guerin. (2012). PET imaging of pulmonary embolism with 18F-Fluorogas and 64Cu-MAA. SNM Annual Meeting, Miami, Fl, June 9-13, 2012, J Nucl Med. 2012; 53 (Supplement 1):487. (Published).
  • Dumulon-Perreault, V.*; Croteau, E.; Ait-Mohand, S.*; Ouellet, R.*; Rousseau, J. A.; Beaudoin, J.-F.; Lecomte, R.; Turcotte, E. E.; Guerin, B. (2012). PET imaging of pulmonary embolism with 18F-Fluorogas and 64Cu-MAA. World Molecular Imaging Congress (WMIC 2012). (Published).
  • N. Cauchon, E. Ranyuk*, B. Guérin, K. Klarskov, J. E. van Lier. (2012). Phthalocyanine-Peptide Conjugates: Receptor-Targeted Bi-Functional Agents for Imaging and Photodynamic Therapy. 36th meeting of the American Society for Photobiology (ASP). (Published).
  • M. Paquette*; É. Lavallée; R. Langlois; E. Croteau; B. Guerin; F. Benard; J.E. van Lier; R. Lecomte; E.E. Turcotte. (2012). Preliminary Results of a Phase II Trial Comparing 4FMFES to FES in PET imaging of Breast Cancer Patients. Journal of Nuclear Medicine, (Published).
  • A. Radulska, S. Ait-Mohand*, V. Dumulon-Perreault*, R. Lebel, R. Zriba, B. Guérin, W.A. Neugebauer, M. Lepage. (2012). Stability studies of peptides specific for MMP-2 as potential PET probes. 22ND European Peptide Symposium. (Published).
  • J. van Lier, E. Ranyuk*, N. Cauchon, H. Ali*, R. Lecomte, B. Guérin. (2012). Synthesis of Cu-64 labelled phthalocyanine-based photosensitizers to generate PET-derived biodistribution patterns for structure-activity relationships. 16th European Symposium on Radiopharmacy and Radiopharmaceuticals April 26-29, 2012 Nantes, France J. Nucl. ed. Mol. Im, 2012;.56, Suppl 1-2, 69-70. (Published).
  • R.Day, F. D’Anjou, F. Couture, C. Levesque, A. Kwaitkowska, S. Routhier, R. Desjardins, B. Guérin, Al. Doueik, M. Carmel, and R. Sabbagh. (2012). Targeting the Proprotein Convertases in Prostate Cancer. 67th Annual Meeting of the Canadian Urological Association - CUA 2012. (Published).
  • A. McEwan, S. McQuarrie, D. Abrams, K. Gagnon, J Wilson, E. Turcotte, B.Guerin, R.Lecomte. (2012). Technetium-99m (Tc-99m) pertechnetate (TcO4) imaging with cyclotron produced Tc-99m compared with generator Tc-99m. SNM Annual Meeting, Miami, Fl, June 9-13, 2012. J Nucl Med. 2012; 53 (Supplement 1):487. (Published).
  • Pourghiasian, M.; Inkster, J.; Hundal, N.; Mesak, F.; Guerin, B.; Ait-Mohand, S.; Ruth,T.; Adam, M.; Lin, K.-S.; Benard, F. (2011). 18F-BVD-15 for NPY Y1 receptor imaging in breast cancer and neuroblastoma models by PET. SNM Annual Meeting, San Antonio, Texas, June 4-8, 2011. J. Nucl Med. 2011; 52 (Supplement 1):1682. (Published).
  • B. Guérin, P. Fournier, V. Dumulon-Perreault, S. Ait-Mohand, R. Lecomte, F. Bénard. (2011). 64Cu/NOTA-[D-Tyr6,?Ala11,Thi13,Nle14]BBN(6-14) monomers and dimers for breast and prostate cancer PET imaging. 19th International Symposium on Radiopharmaceutical Sciences. Amsterdam, The Netherlands, Aug.28-Sept.02, 2011. J Label Compd Radiopharm 2011; 54: S232. (Published).
  • J.A.H.Inkster, K. Liu, P. Schaffer, B. Guerin, T. Ruth, T. Storr. (2011). Assessing the potential of sulfonyl fluorides as 18F-bearing prosthetic molecules. 19th International Symposium on Radiopharmaceutical Sciences. Amsterdam, The Netherlands, Aug.28-Sept.02, 2011. J Label Compd Radiopharm 2011; 54: S75. (Published).
  • Dumulon-Perreault, V.; Ait-Mohand, S.; Fournier, P.; Kiefer, G.; Jurek, P.; Ferreira, C.; Guerin, B. (2011). Bifunctional chelates for 64Cu radiolabelling of BBN peptides for PET imaging, a comparative study. SNM Annual Meeting, San Antonio, Texas, June 4-8, 2011. J. Nucl Med. 2011; 52 (Supplement 1):471. (Published).
  • A.Zyuzin, E. J. van Lier, K. Gagnon, D. Abrams, J Wilson, S. McQuarrie, R. Lecomte, J.E. van Lier, B. Guérin. (2011). Commercializing cyclotron production of 99mTc in Canada: the Canadian ACS-ES approach. 19th International Symposium on Radiopharmaceutical Sciences. Amsterdam, The Netherlands, Aug.28-Sept.02, 2011. J Label Compd Radiopharm 2011; 54: S341. (Published).
  • Fournier, P.; Dumulon-Perreault, V.; Ait-Mohand, S.; Bénard, F.; Lecomte, R.; Guerin, B. (2011). Comparative study of 64Cu/NOTA-[D-Tyr6, ?Ala11, Thi13, Nle14]BBN(6-14) monomer and dimer for breast cancer PET imaging. SNM Annual Meeting, San Antonio, Texas, June 4-8, 2011. J. Nucl Med. 2011; 52 (Supplement 1):1575. (Published).
  • Ranyuk, E.; Cauchon, N.; Ali, H.; Gosselin, S.; Guérin, B.; van Lier, J. (2011). Copper-64 Labeling of phthalocyanine based- Photosensitizers for Positron Emission Tomography. Radiopharmaceuticals and Imaging posters, 94th Canadian Chemistry Conference and Exhibition, Palais des Congrès, Montréal, Qc, Canada, June 5-9, 2011. (Published).
  • Pourghiasian, M.; Inkster, J.; Hundal, N.; Mesak, F.; Guerin, B.; Ait-Mohand, S.; Ruth,T.; Adam, M.; Lin, K.-S.; Benard, F. (2011). Improved tumor targeting of F-18 bombesin analogs labeled by click chemistry is achieved by addition of a PEG side chain. SNM Annual Meeting, San Antonio, Texas, June 4-8, 2011. J. Nucl Med. 2011; 52 (Supplement 1):1579. (Published).
  • Fournier P., A.; Dumulon-Perreault, V.; Ait-Mohand, S.; Bénard, F.; Lecomte, R.; Guérin, B. (2011). Le DOTA-Aoc-BBN(6-14) marqué au 64Cu et 68Ga pour la détection du cancer du sein par imagerie TEP. Congrès de l’ACFAS, Université de Sherbrooke, Sherbrooke, Qc, Canada, May 6-13, 2011. (Published).
  • Ait-Mohand, S.; Ali, H.; Ranyuk, E.; Gosselin, S.; van Lier, J.; Guérin, B. (2011). Les peptides couplés aux phthalocyanines via des réactions de couplage croisé catalisées au palladium pour l’imagerie bimodale de fluorescence et TEP. Congrès de l’ACFAS, Université de Sherbrooke, Sherbrooke, Qc, Canada, May 6-13, 2011. (Published).
  • Rémillard, A.; Ait-Mohand, S.;Bernatchez, G.; Guérin, B. (2011). Nouveaux radiotraceurs peptidiques analogues de la bradykinine pour améliorer le diagnostic du cancer du sein et de la prostate par tomographie d'émission par positrons. 40e Édition de la Journée Scientifique de Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Sherbrooke, Qc, Canada, March 22-23 2011. [Prix FRSQ (CRC Étienne-Le Bel) -. (Published).
  • Fournier, P.; Dumulon-Perreault, V.; Ait-Mohand, S.; Lecomte, R.; Bénard, F.; Guerin, B. (2011). Novel radiolabeled peptides for breast and prostate tumor PET imaging: 64Cu/ and 68Ga/NOTA-PEG-BBN(6-14). SNM Annual Meeting, San Antonio, Texas, June 4-8, 2011. J. Nucl Med. 2011; 52 (Supplement 1):470. (Published).
  • B. Guérin, V. Dumulon-Perreault, E. Croteau, S. Ait-Mohand, R. Ouellet, J. Rousseau, R. Lecomte, E. Turcotte. (2011). PET imaging of pulmonary embolism with 18F-Fluorogas and 64Cu-MAA. 19th International Symposium on Radiopharmaceutical Sciences. Amsterdam, The Netherlands, Aug.28-Sept.02, 2011. J Label Compd Radiopharm 2011; 54: S144. (Published).
  • E. Ranyuk, N. Cauchon, H. Ali, B. Guérin, J.E. van Lier. (2011). Preparation of Cu-64 labeled analogs of phthalocyanine-based photosensitizers for positron emission tomography (PET) imaging and in vivo studies of phthalocyanine biodistribution. 19th International Symposium on Radiopharmaceutical Sciences. Amsterdam, The Netherlands, Aug.28-Sept.02, 2011. J Label Compd Radiopharm 2011; 54: S129. (Published).
  • Fournier P., A.; Ait-Mohand, S.; Dumulon-Perreault, V.; Guérin, B. (2011). Étude comparative in vitro des dérivés du BBN(6-14) radiomarqués au 64Cu et 68Ga pour la détection du cancer du sein par imagerie TEP. 40e Édition de la Journée Scientifique de Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Sherbrooke, Qc, Canada, March 22-23 2011. (Published).
  • Guérin, B.; Zyuzin, A.; Tremblay, S.; van Lier, E.; Rodrigue, S.; Rousseau, J.; Dumulon-Perreault, V.; Lecomte, R; van Lier, J. E. (2010). Comparing cyclotron- with generator-produced Tc-99m. International Symposium on Technetium and other Radiometals in Chemistry and Medicine, Bressanone (BZ), Italy. (Published).
  • A. Zyuzin, B. Guérin, E.J. van Lier, S. Tremblay, S. Rodrigue, J.A. Rousseau, V. Dumulon-Perreault, R. Lecomte, J.E. van Lier. (2010). Cyclotron production of 99mTc. 13th International Workshop on Targetry and Target Chemistry, Roskilde, Denmark. (Published).
  • Guérin, B.; Zyuzin, A.; Tremblay, S.; van Lier, E.; Rodrigue, S.; Rousseau, J.; Dumulon-Perreault, V.; Lecomte, R; van Lier, J. E. (2010). Direct production of 99mTc with a medical cyclotron?. Pacifichem 2010, Honolulu, Hawaï, USA,. (Published).
  • B. Guérin, A. Zyuzin, S. Tremblay, E.J. van Lier, S. Rodrigue, J.A. Rousseau, V. Dumulon-Perreault, R. Lecomte, J.E. van Lier. (2010). Direct production of 99mTc with a medical cyclotron?. Society of Nuclear Medicine 57th Annual Meeting, Salt Lake City, Utah Inclusion in the “high-lights” lecture. (Published).
  • Labbé SM, Ouellet R, van Lier JE, Guérin B, Lecomte R, Carpentier A. (2010). Impact des gras alimentaires dans le developpement de la lipotoxicite des tissus non-adipeux. 11e réunion annuelle de la SQLNM, Prix de la meilleure présentation poster au niveau doctoral. (Published).
  • P Fournier, S Ait-Mohand, V Dumulon-Perreault et B Guérin. (2010). In vitro comparative study of DOTA- and NOTA-BBN(6-14) radiolabelled with 64Cu for breast cancer PET imaging. Colloque Uppsala /Sherbrooke, Université de Sherbrooke, Sherbrooke, Qc, Canada. (Published).
  • Turashvili G, Aparicio S, Guérin B, Watson P, Bénard F. (2010). Overexpression of peptide receptors as target for PET or SPECT radiopharmaceuticals: a tissue microarray study (TMA). Society of Nuclear Medicine 57th Annual Meeting, Salt Lake City, Utah. (Published).
  • P Fournier, S Ait-Mohand, V Dumulon-Perreault et B Guérin. (2010). Peptides radiomarqués au Cuivre-64 et au Gallium-68 pour la détection du cancer du sein par tomographie d’émission par positron. 39e Édition de la Journée Scientifique de Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Sherbrooke, Qc, Canada Prix Jean-Marie Beauregard. (Published).
  • Guérin, B.; Ali, H.; Ait-Mohand, S.; Gosselin, S.; van Lier, J. E. (2010). Phthalocyanine-functionalized peptides via palladium-catalyzed cross-coupling reactions. Pacifichem 2010, Honolulu, Hawaï, USA,. (Published).
  • E.J. van Lier, J. Garret, B. Guérin, S. Rodrigue, J.E. van Lier, S. McQuarrie, J. Wilson, K. Gagnon, M.S. Kovacs, J. Burbee, A. Zyuzin,. (2010). Targets for Cyclotron Production of Tc-99m. 13th International Workshop on Targetry and Target Chemistry, Roskilde, Denmark. (Published).
  • Fournier,P.; Ait-Mohand, S.; Dumulon-Perreault, V.; Guérin, B. (2010). Étude compartive in vitro de derivés du BBN(6-14) radio marqués au 64Cu et au 68Ga pour la détection du cancer du sein par imagerie TEP. Journée Phare 2010 de l’Université de Sherbrooke , Sherbrooke, QC, Canada. (Published).

Propriétés intellectuelles

Patents

  • (2006). New peptidic and peptidoid bradykinin b1 receptor antagonists and uses thereof. WO 2006017938 A1. Canada. (Granted/Issued).
  • Rahimipour, S.; Habashi, M.; Richman, M.; Lubell, W.D.; Chauhan, P.S.; Vutla, S.; Chingle, R.; Ait-Mohand, S.; Dumulon-Perreault, V.; Guérin, B. Azacyclopeptides for early assessment and therapy of amyloid disease pathology. US 63/077,627. Israel. (Pending).
  • Guérin, B; Beaudoin, J.-F.; Tremblay, S. CARRIER FOR IRRADIATED TARGET AND DISSOLUTION SYSTEM FOR PRODUCING SOLUTION OF SAME. US 62/833,058. Canada. (Pending).
  • Guérin, B; Ait-Mohand, S.;Tremblay,S.; Maier, M.; Salzmann, M. In vivo imaging of an ALS biomarker and means therefor. EP 23 169 614.7.. Canada. (Pending).
  • Gobeil, F.; Guérin, B; Lepage, M.; Sabbagh, R.; Fortin, D. NOVEL KININ-BASED THERANOSTIC PROBES FOR SOLID CANCERS (AS BRAIN TUMORS) AND USES THEREOF. PCT/CA2016/050732. Canada. (Pending).
  • Guérin, B; Tremblay, S.; Ait-Mohand, S.; Alnahwi, AH. PROCESSES AND SYSTEMS FOR PRODUCING AND/OR PURIFYING GALLIUM-68. 62/777,994 USPR. Canada. (Pending).
  • Guérin, B; Ouellet, R.; Tremblay, S. PROCESSES FOR OBTAINING TECHNETIUM-99M AND/OR MOLYBDENUM(VI) OXIDE. 05202424-36CA. Canada. (Pending).
  • RADIOLABELLED PACE4 INHIBITOR FOR MOLECULAR IMAGING AND TARGETED THERAPY OF CANCER. Canada. (Pending).

Licenses

  • PROCESSES AND SYSTEMS FOR PRODUCING AND/OR PURIFYING GALLIUM-68. (2019). (Granted).

Autres contributions

Gestion d'évènements

  • Organizing Committee, Local. (2012) 10th International NPY-PYY-PP meeting. (Conference).

Activités de collaboration internationale

  • Expert in radiochemistry. Austria. 2nd Research Coordination Meeting on Copper-64Radiopharmaceuticals for Theranostic Applications 7-11 May 2018, IAEAHeadquarters Vienna, Austria.
  • Expert in radiochemistry,. Austria. Consultants’ Meeting on Formulationof an IAEA TECDOC on “Ga-68 Cyclotron Production” 26-29 March 2018, IAEAHeadquarters.
  • Expert in radiochemistry. Saudi Arabia. Presentations given at Riyadh and Jeddah on the feasibility ofcyclotron-based production of medical 99mTc, as an alternativeto nuclear-reactor based procedures.

Présentations

  • W. Lubell and S.Rahimipour. (2024). Early diagnosis and treatment of Alzheimer’s disease by targeting toxic soluble Aβ oligomers. Guess Symposium by Zoom, Presentation Mount-Sinai- project AD. Canada
  • (2024). Production and Quality Control of Cyclotron Based Ga-68 Radiopharmaceuticals. IAEA Webinar “Cyclotron Based Production of Ga-68 radiopharmaceuticals. Canada
  • (2023). 89Zr-PET imaging agent targeting SOD-1 for the detection of ALS. Rencontre annuelle du Consortium Acuité-Québec. Bromont, Canada
  • (2022). Development of 64Cu/NOTA-terpyridine platinum conjugates as potential chemoradiotheranostic agents. CANUK 2022 : Canada - UK Joint Symposium on Coordination. St-Andrews, United Kingdom
  • (2022). New PET Tracers and Radioligands - From Production to Translation. Chemistry seminar -Dalousie Lecture. Canada
  • (2022). PET Tracers and Radioligands - From Production to Translation. Webinaires Protéo. Canada
  • (2022). Production de technétium par cyclotron, où en sommes-nous?. 40E Colloque de L’AMSMNQ. Sherbrooke, Canada
  • (2022). The triple-tracer molecular imaging for metastatic prostate cancer patients: from cyclotron vault to clinical use. Invited Guest Speaker - Department of Pharmaceutical Sciences, University of Toronto. Toronto, Canada
  • (2021). Optimizing care for metastatic prostate cancer patients with a triple-tracer molecular imaging. Urology (Research Seminar) Invited Guest Speaker, Sherbrooke. Canada
  • (2021). The triple-tracer molecular imaging for metastatic prostate cancer patients: from cyclotron vault to clinical use. Invited Guest Speaker - Department of Pharmaceutical Sciences- Toronto. Canada
  • (2021). The triple-tracer molecular imaging for optimizing care for metastatic prostate cancer patients. Invited Guest Speaker - McGill University Urology -Montreal-. Canada
  • (2020). 64Cu-Radiopharmaceuticals for Theranostic Applications; a Canadian Experience. 3rd Research Coordination Meeting on Copper-64 Radiopharmaceuticals for Theranostic Applications. Austria
  • (2019). Cyclotron Production of Zr-89 and Ga-68 Using Pressed Targets. TRIUMF Science week. Vancouver. Canada
  • (2019). Development and evaluation of chelators for specific radiometals. International Symposium on Trends in Radiopharmaceuticals (ISTR-2019). Austria
  • (2019). ONCOPOLE : Optimiser les soins des patients atteints du cancer de la prostate résistant à la castration en utilisant une stratégie de triple traceur en imagerie moléculaire et en radiothérapie ciblée. Symposium de la recherche sur le cancer,Sherbrooke. Canada
  • (2019). Optimizing care for prostate cancer patients using molecular imaging and targeted radioligand therapy. 11th Scientific Day QBIN, Montreal. Canada
  • (2019). Our experience on metallic radiopharmaceuticals Development of 68Ga-Octreotate and 68Ga-PSMA for molecular imaging using 68Ga-produced by cyclotron. CONSULTANTS’ MEETING (EVT1701715), IAEA Headquarters, Vienna. Austria
  • (2019). Preclinical evaluation of 68Ga-PET tracers using 68Ga produced by cyclotron, a Canadian experience. International Symposium on Trends in Radiopharmaceuticals (ISTR-2019). Austria
  • (2018). 18F-labelled BODIPY-steroid conjugates as potential bimodal imaging agents. Tenth International Conference on Porphyrins & Phthalocyanines, ICPP?10. Munich, Germany
  • (2018). Cyclotron production of 68Ga via 68Zn(p,n)68Ga reaction using pressed target. Consultants’ Meeting on Formulation of an IAEA TECDOC on “Ga-68 Cyclotron Production. Vienna, Austria
  • (2018). New 64Cu peptides for prostate and breast cancers for PET imaging. 2nd Research Coordination Meeting on Copper-64 Radiopharmaceuticals for Theranostic Applications. Vienna, Austria
  • (2018). Optimizing care for castration-resistant prostate cancer patients using triple-tracer molecular imaging and targeted radioligand therapy. Symposium Oncopole. Canada
  • (2018). Outils pour l’imagerie TEP, une ouverture vers le développement de théranostiques. Lecture at UQAM's chemistry department. Canada
  • (2018). Tools for peptide radiolabeling, Clara Benson Award Lecture. 101st Canadian Chemistry Conference and Exhibition. Edmonton, Canada
  • Martin Savard, Veronique Dumulon-Perreault, Celena Dubuc, Samia Ait-Mohand, Fernand jr Gobeil. (2017). Theranostic potential of a new 64Cu-radiolabeled peptide conjugate for kinin B1R positive tumors. BIT’s 10th Annual World Cancer Congress, WCC 2017. Spain
  • (2016). BODIPY-estradiol conjugates as multi-modality tumor imaging agents. Ninth International Conference on Porphyrins and Phthalocyanines (ICPP9). Nanjing, China
  • (2015). Produire des isotopes médicaux sans réacteur nucléaire. Symposium mondial sur l’uranium. Québec, Canada
  • Alex Zyuzin. (2015). Project for Producing Tc-99m for Medical Use. State of Molybdenum-99 Production and Utilization and Progress toward Eliminating Use of Highly Enriched Uranium. Ottawa, Canada
  • (2013). Development of PET radioeptides to Improve Cancer Diagnostic. Radiochemistry Symposium, 96th Canadian Chemistry Conference and Exhibition,. Québec, Canada
  • (2012). Radiolabelled NPY peptides to improve cancer diagnosis by PET. 10th International NPY-PYY-PP meeting. Canada, Canada
  • (2012). TR-24 Canadian experience. Invitation of the Saudi Arabian National Guard. Riyadh, Saudi Arabia, Saudi Arabia
  • (2011). Optimization and Biological Evaluation of Radiolabelled Peptides as Diagnostic Tools for PET Imaging. Peptide Science Symposium, 94th Canadian Chemistry Conference and Exhibition. Montréal, Canada
  • (2011). Radiolabelled Peptides to Improve Cancer Diagnostic by Positron Emission Tomography. Radiopharmaceuticals and Imaging Symposium, 94th Canadian Chemistry Conference and Exhibition. Montréal, Canada